Ausgewählte Publikationen

Zech HB, Schafhausen P, Ramke L, Velthaus JL, Kreutzfeldt S, Hübschmann D, Rothkamm K, Bokemeyer C, Hoffmann AS, Fröhling S, Glimm H, Betz CS, Kriegs M, Christopeit M. Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization. Biomedicines. 2025 May 21;13(5):1266. doi: 10.3390/biomedicines13051266. PMID: 40427091; PMCID: PMC12108840.
Teleanu MV, Schneider A, Ball CR, Leber MF, Stange C, Krieghoff-Henning E, Beck K, Heilig CE, Kreutzfeldt S, Kuster B, Lipka DB, Fröhling S. Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment. Biomolecules. 2025 May 10;15(5):693. doi: 10.3390/biom15050693. PMID: 40427586; PMCID: PMC12108785.
Mohanty S, Charles Cano F, Gabdoulline R, Lai CK, Othman B, Sudarsanam H, Eder T, Grebien F, Lipka DB, Henschler R, Heuser M. Clec12a is required for the pathogenesis of NUP98::NSD1 AML. Blood Adv. 2025 May 7:bloodadvances.2024015739. doi: 10.1182/bloodadvances.2024015739. Epub ahead of print. PMID: 40334081.
Möhrmann L, Werner M, Oleś M, Knol L, Arnold JS, Mundt T, Paramasivam N, Richter D, Fröhlich M, Hutter B, Hüllein J, Jahn A, Scheffold C, Möhrmann EE, Hanf D, Kreutzfeldt S, Heilig CE, Teleanu MV, Lipka DB, Beck K, Baude-Müller A, Jelas I, Rieke DT, Klotz LV, Shah R, Herold T, Boerries M, Illert AL, Allgäuer M, Stenzinger A, Kerle IA, Horak P, Heining C, Schröck E, Hübschmann D, Fröhling S, Glimm H. Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma. ESMO Open. 2025 Apr 1;10(4):104532. doi: 10.1016/j.esmoop.2025.104532. Epub ahead of print. PMID: 40174508.
Sollier E, Riedel A, Toprak UH, Wierzbinska JA, Weichenhan D, Schmid JP, Hakobyan M, Touzart A, Jahn E, Vick B, Brown-Burke F, Kelly K, Kelekci S, Pejkovska A, Goyal A, Bähr M, Breuer K, Chen MM, Llamazares-Prada M, Hartmann M, Schönung M, Correia N, Trumpp A, Abdullah Y, Klingmüller U, Mughal SS, Brors B, Westermann F, Ulrich E, Autry RJ, Schlesner M, Vosberg S, Herold T, Greif PA, Pfeifer D, Lübbert M, Fischer T, Heidel FH, Gebhard G, Walter W, Haferlach T, Eisfeld AK, Mrózek K, Nicolet D, Bullinger L, Smeenk L, Erpelinck-Verschueren C, Mulet-Lazaro R, Delwel R, Ernst A, Scherer M, Lutsik P, Jeremias I, Döhner K, Döhner H, Lipka DB, Plass C. Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q. Blood Cancer Discov. 2025 Mar 31. doi: 10.1158/2643-3230.BCD-24-0278. Epub ahead of print. PMID: 40162972.
Möhrmann L, Rostock L, Werner M, Oleś M, Arnold JS, Paramasivam N, Jöhrens K, Rupp L, Schmitz M, Richter D, Uhrig S, Fröhlich M, Hutter B, Hüllein J, Jahn A, Arlt M, Möhrmann EE, Hanf D, Gieldon L, Kreutzfeldt S, Heilig CE, Teleanu MV, Lipka DB, Beck K, Baude-Müller A, Mock A, Jelas I, Rieke DT, Wiesweg M, Brandts C, Boerries M, Illert AL, Desuki A, Kindler T, Krackhardt AM, Westphalen CB, Christopoulos P, Apostolidis L, Stenzinger A, Allgäuer M, Neumann O, Kerle IA, Horak P, Heining C, Grosch H, Schröck E, Hübschmann D, Fröhling S, Glimm H. Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. Med. 2025 Mar 13:100612. doi: 10.1016/j.medj.2025.100612. Epub ahead of print. PMID: 40107270.
Lutz R, Poos AM, Solé-Boldo L, John L, Wagner J, Prokoph N, Baertsch MA, Vonficht D, Palit S, Brobeil A, Mechtersheimer G, Hildenbrand N, Hemmer S, Steiger S, Horn S, Pepke W, Spranz DM, Rehnitz C, Sant P, Mallm JP, Friedrich MJ, Reichert P, Huhn S, Trumpp A, Rippe K, Haghverdi L, Fröhling S, Müller-Tidow C, Hübschmann D, Goldschmidt H, Willimsky G, Sauer S, Raab MS, Haas S, Weinhold N. Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma. Sci Immunol. 2025 Feb 7;10(104):eadp6667. doi: 10.1126/sciimmunol.adp6667. Epub 2025 Feb 7. PMID: 39919199.
Marmé F, Krieghoff-Henning EI, Kiehl L, Wies C, Hauke J, Hahnen E, Harter P, Schouten PC, Brodkorb T, Kayali M, Heitz F, Zamagni C, González-Martin A, Treilleux I, Kommoss S, Prieske K, Gaiser T, Fröhling S, Ray-Coquard I, Pujade-Lauraine E, Brinker TJ. Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides. Eur J Cancer. 2025 Feb 5;216:115199. doi: 10.1016/j.ejca.2024.115199. Epub 2024 Dec 26. PMID: 39742559.
Behjati S, Boehm JS, Dun MD, Fröhling S, Huang PH, Jabado N, Li N, Robles-Espinoza CD. Think zebras: challenges and opportunities for treating rare cancers. Trends Cancer. 2025 Jan 28:S2405-8033(25)00005-6. doi: 10.1016/j.trecan.2025.01.004. Epub ahead of print. PMID: 39875305.
Casali PG, Antoine-Poirel H, Berrocoso S, Blay JY, Dubois T, Ferrari A, Fullaondo A, Hovig E, Jagodzińska-Mucha P, Ługowska I, Kaasa S, Nicoară D, Pletsa V, Provenzano S, Santoro M, Šekerija M, Van Hoof W, Vyas M, Trama A; JANE Consortium. Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE). ESMO Open. 2025 Feb;10(2):104126. doi: 10.1016/j.esmoop.2024.104126. Epub 2025 Jan 27. PMID: 39874899; PMCID: PMC11799966.
Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M. Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. J Cancer Res Clin Oncol. 2025 Jan 18;151(1):39. doi: 10.1007/s00432-024-06060-2. Erratum for: J Cancer Res Clin Oncol. 2023 Feb;149(2):913-919. doi: 10.1007/s00432-022-04407-1. PMID: 39825921; PMCID: PMC11742772.
Haggenmüller S, Wies C, Abels J, Winterstein JT, Heinlein L, Nogueira Garcia C, Utikal JS, Wohlfeil SA, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Sarfert C, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Llamas-Velasco M, Requena LC, Ferrara G, Fernandez-Figueras M, Fraitag S, Müller CSL, Starz H, Kutzner H, Barnhill R, Carr R, Resnik KS, Braun SA, Holland-Letz T, Brinker TJ. Discordance, accuracy and reproducibility study of pathologists' diagnosis of melanoma and melanocytic tumors. Nat Commun. 2025 Jan 17;16(1):789. doi: 10.1038/s41467-025-56160-x. PMID: 39824857; PMCID: PMC11742048.
Kerle IA, Gross T, Kögler A, Arnold JS, Werner M, Eckardt JN, Möhrmann EE, Arlt M, Hutter B, Hüllein J, Richter D, Schneider MMK, Hlevnjak M, Möhrmann L, Hanf D, Heilig CE, Kreutzfeldt S, Teleanu MV, Schröck E, Hübschmann D, Horak P, Heining C, Fröhling S, Glimm H. Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncology. NPJ Precis Oncol. 2025 Jan 10;9(1):9. doi: 10.1038/s41698-024-00788-3. PMID: 39794422; PMCID: PMC11724059.

Marmé F, Krieghoff-Henning EI, Kiehl L, Wies C, Hauke J, Hahnen E, Harter P, Schouten PC, Brodkorb T, Kayali M, Heitz F, Zamagni C, González-Martin A, Treilleux I, Kommoss S, Prieske K, Gaiser T, Fröhling S, Ray-Coquard I, Pujade-Lauraine E, Brinker TJ. Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides. Eur J Cancer. 2024 Dec 26;216:115199. doi: 10.1016/j.ejca.2024.115199. Epub ahead of print. PMID: 39742559.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, Ambrosini P, Fotia G, Hüllein J, Randon G, Lajer P, Perrone F, Tamborini E, Leoncini G, Coppa J, Busset MDD, Pusceddu S, Milione M, Morano F, Pietrantonio F, Pruneri G, Mazzaferro V, Lipka DB, Köhler BC, Hübschmann D, Fröhling S, de Braud F, Niger M. Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. Cancer Med. 2024 Dec;13(23):e70393. doi: 10.1002/cam4.70393. PMID: 39618336; PMCID: PMC11609587.
van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024 Nov;35(11):954-967. doi: 10.1016/j.annonc.2024.06.018. Epub 2024 Jul 9. PMID: 39112111.
van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024 Nov;35(11):954-967. doi: 10.1016/j.annonc.2024.06.018. Epub 2024 Jul 9. PMID: 39112111.
Xu K, Kessler A, Nichetti F, Hoffmeister-Wittmann P, Scherr AL, Nader L, Kelmendi E, Schmitt N, Schwab M, García-Beccaria M, Sobol B, Nieto OA, Isele H, Gärtner U, Vaquero-Siguero N, Volk J, Korell F, Mock A, Heide D, Ramadori P, Lenoir B, Albrecht T, Hüllein J, Jäger D, Fröhling S, Springfeld C, Jackstadt R, Heikenwälder M, Dill MT, Roessler S, Goeppert B, Köhler BC. Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. Liver Int. 2024 Nov;44(11):2950-2963. doi: 10.1111/liv.16069. Epub 2024 Aug 20. PubMed PMID: 39164890.
Heinst L, Lee KS, Berthold R, Isfort I, Wosnig S, Kuntze A, Hafner S, Altvater B, Rossig C, Åman P, Wardelmann E, Scholl C, Hartmann W, Fröhling S, Trautmann M. Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma. Clin Cancer Res. 2024 Nov 1;30(21):4974-4986. doi: 10.1158/1078-0432.CCR-24-1152. PubMed PMID: 39207225.
Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, Boerries M, Wolter S, Ball M, Neumann O, Armeanu-Ebinger S, Schroeder C, Matysiak U, Goldschmid H, Schipperges V, Fürstberger A, Allgäuer M, Eberhardt T, Niewöhner J, Blaumeiser A, Ploeger C, Haack TB, Tay TKY, Kelemen O, Pauli T, Kirchner M, Kluck K, Ott A, Renner M, Admard J, Gschwind A, Lassmann S, Kestler H, Fend F, Illert AL, Werner M, Möller P, Seufferlein TTW, Malek N, Schirmacher P, Fröhling S, Kazdal D, Budczies J, Stenzinger A. Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients. NPJ Precis Oncol. 2023 Oct 20;7(1):106. doi: 10.1038/s41698-023-00457-x. PMID: 37864096; PMCID: PMC10589320.
Tremmel R, Hübschmann D, Schaeffeler E, Pirmann S, Fröhling S, Schwab M. Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes. Pharmacol Rev. 2024 Oct 15;. doi: 10.1124/pharmrev.124.001049. [Epub ahead of print] PubMed PMID: 39406507.
Weichenhan D, Riedel A, Sollier E, Toprak UH, Hey J, Breuer K, Wierzbinska JA, Touzart A, Lutsik P, Bähr M, Östlund A, Nilsson T, Jacobsson S, Edler M, Waraky A, Behrens YL, Göhring G, Schlegelberger B, Steinek C, Harz H, Leonhardt H, Dolnik A, Reinhardt D, Bullinger L, Palmqvist L, Lipka DB, Plass C. Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13). Blood Adv. 2024 Oct 8;8(19):5100-5111. doi: 10.1182/bloodadvances.2023012161. PMID: 39121370; PMCID: PMC11460460.
Ball CR, Fröhling S. Let's get functional: Drug sensitivity profiling to enable precision sarcoma medicine. Cell Stem Cell. 2024 Oct 3;31(10):1389-1390. doi: 10.1016/j.stem.2024.09.006. PubMed PMID: 39366358.
Heinst L, Lee KS, Berthold R, Isfort I, Wosnig S, Kuntze A, Hafner S, Altvater B, Rössig C, Åman P, Wardelmann E, Scholl C, Hartmann W, Fröhling S, Trautmann M. Exploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma. Clin Cancer Res. 2024 Aug 29;. doi: 10.1158/1078-0432.CCR-24-1152. [Epub ahead of print] PubMed PMID: 39207225.
Scherr AL, Nader L, Xu K, Elssner C, Ridder DA, Nichetti F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, Hoffmeister-Wittmann P, Weiler SME, Korell F, Albrecht T, Schwab M, Isele H, Kessler A, Hüllein J, Seretny A, Ye L, Urbanik T, Welte S, Leblond AL, Heilig CE, Rahbari M, Ali A, Gallage S, Lenoir B, Wilhelm N, Gärtner U, Ogrodnik SJ, Springfeld C, Tschaharganeh D, Fröhling S, Longerich T, Schulze-Bergkamen H, Jäger D, Brandl L, Schirmacher P, Straub BK, Weber A, De Toni EN, Goeppert B, Heikenwalder M, Jackstadt R, Roessler S, Breuhahn K, Köhler BC. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC. Hepatology. 2024 Aug 1;80(2):278-294. doi: 10.1097/HEP.0000000000000657. Epub 2023 Nov 2. PubMed PMID: 37916976.
Xu K, Kessler A, Nichetti F, Hoffmeister-Wittmann P, Scherr AL, Nader L, Kelmendi E, Schmitt N, Schwab M, García-Beccaria M, Sobol B, Nieto OA, Isele H, Gärtner U, Vaquero-Siguero N, Volk J, Korell F, Mock A, Heide D, Ramadori P, Lenoir B, Albrecht T, Hüllein J, Jäger D, Fröhling S, Springfeld C, Jackstadt R, Heikenwälder M, Dill MT, Roessler S, Goeppert B, Köhler BC. Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. Liver Int. 2024 Aug 20;. doi: 10.1111/liv.16069. [Epub ahead of print] PubMed PMID: 39164890.
Salek M, Förster JD, Becker JP, Meyer M, Charoentong P, Lyu Y, Lindner K, Lotsch C, Volkmar M, Momburg F, Poschke I, Fröhling S, Schmitz M, Offringa R, Platten M, Jäger D, Zörnig I, Riemer AB. optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material. Mol Cell Proteomics. 2024 Sep;23(9):100825. doi: 10.1016/j.mcpro.2024.100825. Epub 2024 Aug 5. PubMed PMID: 39111711; PubMed Central PMCID: PMC11405902.
Brinker TJ, Krieghoff-Henning EI, Suhre JL, Silchmüller MP, Divizieva E, Wilhelm J, Hillebrand G, Haney AC, Srivastava A, Haney CM, Seeger W, Penka D, Gall H, Gaim B, Glisic L, Stark T, Swoboda SM, Baumermann S, Brieske CM, Jakob L, Fahrner HM, Anhuef O, Schmidt SM, Alfitian J, Taha L, Beißwenger H, Groneberg DA, Thomas RE, Fröhling S, von Kalle C, Baudson TG, Buslaff F, Mons U. Evaluation of a medical student-delivered smoking prevention program utilizing a face-aging mobile app for secondary schools in Germany: The Education Against Tobacco cluster-randomized controlled trial. Eur J Cancer. 2024 Sep;209:114255. doi: 10.1016/j.ejca.2024.114255. Epub 2024 Aug 2. PubMed PMID: 39111207.
van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024 Jul 9:S0923-7534(24)01011-1. doi: 10.1016/j.annonc.2024.06.018. Epub ahead of print. PMID: 39112111.
Haage TR, Charakopoulos E, Bhuria V, Baldauf CK, Korthals M, Handschuh J, Müller P, Li J, Harit K, Nishanth G, Frey S, Böttcher M, Fischer KD, Dudeck J, Dudeck A, Lipka DB, Schraven B, Green AR, Müller AJ, Mougiakakos D, Fischer T. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia. J Hematol Oncol. 2024 Jun 9;17(1):43. doi: 10.1186/s13045-024-01562-5. PMID: 38853260; PMCID: PMC11163796.
Haggenmüller S, Maron RC, Hekler A, Krieghoff-Henning E, Utikal JS, Gaiser M, Müller V, Fabian S, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, Weichenthal M, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Kaminski K, Doppler A, Bucher T, Brinker TJ. Patients' and dermatologists' preferences in artificial intelligence-driven skin cancer diagnostics: A prospective multicentric survey study. J Am Acad Dermatol. 2024 Aug;91(2):366-370. doi: 10.1016/j.jaad.2024.04.033. Epub 2024 Apr 24. PubMed PMID: 38670313
Carmona J, Chavarria E, Donoghue K, von Gertten C, Oberrauch P, Pailler E, Scoazec G, Weijer R, Balmaña J, Brana I, Brunelli C, Delaloge S, Deloger M, Delpy P, Ernberg I, Fitzgerald RC, Garralda E, Lablans M, Lëhtio J, Lopez C, Fernández M, Miceli R, Nuciforo P, Perez-Lopez R, Provenzano E, Schmidt MK, Serrano C, Steeghs N, Tamborero D, Wirta V, Baird RD, Barker K, Barlesi F, Baumann M, Bergh J, de Braud F, Fizazi K, Fröhling S, Piris-Giménez A, Seamon K, Van der Heijden MS, Zwart W, Tabernero J. Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally. Cancer Discov. 2024 Jul 1;14(7):1147-1153. doi: 10.1158/2159-8290.CD-24-0377. PMID: 38870393.
Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgäuer M, Tay TKY, Schnecko F, Volckmar AL, Goldschmid H, Neuman O, Fröhling S, Schirmacher P, Budczies J, Stenzinger A, Kazdal D. Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in Tumor. J Mol Diagn. 2024 Jun;26(6):479-486. doi: 10.1016/j.jmoldx.2024.02.008. Epub 2024 Mar 22. PMID: 38522840.
Haage TR, Charakopoulos E, Bhuria V, Baldauf CK, Korthals M, Handschuh J, Müller P, Li J, Harit K, Nishanth G, Frey S, Böttcher M, Fischer KD, Dudeck J, Dudeck A, Lipka DB, Schraven B, Green AR, Müller AJ, Mougiakakos D, Fischer T. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia. J Hematol Oncol. 2024 Jun 9;17(1):43. doi: 10.1186/s13045-024-01562-5. PMID: 38853260; PMCID: PMC11163796.
Mack E, Horak P, Fröhling S, Neubauer A. Präzisionsonkologie und molekulare Tumorboards [Precision oncology and molecular tumor boards]. Inn Med (Heidelb). 2024 May;65(5):462-471. German. doi: 10.1007/s00108-024-01689-0. Epub 2024 Apr 23. PMID: 38652307.
Haggenmüller S, Maron RC, Hekler A, Krieghoff-Henning E, Utikal JS, Gaiser M, Müller V, Fabian S, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, Weichenthal M, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Kaminski K, Doppler A, Bucher T, Brinker TJ; Collaborators. Patients' and dermatologists' preferences in artificial intelligence-driven skin cancer diagnostics: A prospective multicentric survey study. J Am Acad Dermatol. 2024 Apr 24:S0190-9622(24)00649-2. doi: 10.1016/j.jaad.2024.04.033. Epub ahead of print. PMID: 38670313.
Wagner J, Fröhling S. Sarcoma ecotypes determine immunotherapy benefit. Nat Cancer. 2024 Apr;5(4):536-538. doi: 10.1038/s43018-024-00762-9. PMID: 38684825.
Martins LR, Sieverling L, Michelhans M, Schiller C, Erkut C, Grünewald TGP, Triana S, Fröhling S, Velten L, Glimm H, Scholl C. Single-cell division tracing and transcriptomics reveal cell types and differentiation paths in the regenerating lung. Nat Commun. 2024 Mar 12;15(1):2246. doi: 10.1038/s41467-024-46469-4. PMID: 38472236; PMCID: PMC10933319.
Rheinnecker M, Fröhlich M, Rübsam M, Paramasivam N, Heilig CE, Fröhling S, Schlenk RF, Hutter B, Hübschmann D. ZygosityPredictor. Bioinform Adv. 2024 Feb 6;4(1):vbae017. doi: 10.1093/bioadv/vbae017. PMID: 38560552; PMCID: PMC10980564.
Haggenmüller S, Schmitt M, Krieghoff-Henning E, Hekler A, Maron RC, Wies C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Brinker TJ. Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics. JAMA Dermatol. 2024 Feb 7:e235550. doi: 10.1001/jamadermatol.2023.5550. Epub ahead of print. PMID: 38324293; PMCID: PMC10851139.
Chanda T, Hauser K, Hobelsberger S, Bucher TC, Garcia CN, Wies C, Kittler H, Tschandl P, Navarrete-Dechent C, Podlipnik S, Chousakos E, Crnaric I, Majstorovic J, Alhajwan L, Foreman T, Peternel S, Sarap S, Özdemir İ, Barnhill RL, Llamas-Velasco M, Poch G, Korsing S, Sondermann W, Gellrich FF, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Goebeler M, Schilling B, Utikal JS, Ghoreschi K, Fröhling S, Krieghoff-Henning E; Reader Study Consortium; Brinker TJ. Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma. Nat Commun. 2024 Jan 15;15(1):524. doi: 10.1038/s41467-023-43095-4. PMID: 38225244; PMCID: PMC10789736.
Horak P, Fröhling S. Measuring Progress in Precision Oncology. Cancer Discov. 2024 Jan 12;14(1):18-19. doi: 10.1158/2159-8290.CD-23-1237. PMID: 38213297.
Hamacher R, Pabst KM, Cheung PF, Heilig CE, Hüllein J, Liffers ST, Borchert S, Costa PF, Schaarschmidt BM, Kessler L, Miera MA, Droste M, Akbulut M, Falkenhorst J, Zarrad F, Kostbade K, Mavroeidi IA, Glimm H, Umutlu L, Schuler M, Hübschmann D, Bauer S, Fröhling S, Herrmann K, Siveke JT, Schildhaus HU, Fendler WP. Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor. J Nucl Med. 2024 Jan 4:jnumed.123.266411. doi: 10.2967/jnumed.123.266411. Epub ahead of print. PMID: 38176718.
Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, Eichmüller SB, Steinberger P, Lindner K, Poschke I, Platten M, Fröhling S, Riemer AB, Hassel JC, Roberti MP, Jäger D, Zörnig I, Momburg F. MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection. Front Immunol. 2024 Jan 4;14:1294565. doi: 10.3389/fimmu.2023.1294565. PMID: 38239352; PMCID: PMC10794645.
Schöpf J, Uhrig S, Heilig CE, Lee KS, Walther T, Carazzato A, Dobberkau AM, Weichenhan D, Plass C, Hartmann M, Diwan GD, Carrero ZI, Ball CR, Hohl T, Kindler T, Rudolph-Hähnel P, Helm D, Schneider M, Nilsson A, Øra I, Imle R, Banito A, Russell RB, Jones BC, Lipka DB, Glimm H, Hübschmann D, Hartmann W, Fröhling S, Scholl C. Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions. Nat Commun. 2024 Jan 2;15(1):51. doi: 10.1038/s41467-023-44360-2. PMID: 38168093; PMCID: PMC10761971.

Scherr AL, Nader L, Xu K, Elssner C, Ridder DA, Nichetti F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, Hoffmeister-Wittmann P, Weiler SME, Korell F, Albrecht T, Schwab M, Isele H, Kessler A, Hüllein J, Seretny A, Ye L, Urbanik T, Welte S, Leblond AL, Heilig CE, Rahbari M, Ali A, Gallage S, Lenoir B, Wilhelm N, Gärtner U, Ogrodnik SJ, Springfeld C, Tschaharganeh D, Fröhling S, Longerich T, Schulze-Bergkamen H, Jäger D, Brandl L, Schirmacher P, Straub BK, Weber A, De Toni EN, Goeppert B, Heikenwalder M, Jackstadt R, Roessler S, Breuhahn K, Köhler BC. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma. Hepatology. 2023 Nov 2;. doi: 10.1097/HEP.0000000000000657. Epub ahead of print. PMID: 37916976.
Willis F, Buck L, Musa J, Hinz U, Mechtersheimer G, Seidensaal K, Fröhling S, Büchler MW, Schneider M. Long-term quality of life after resection of retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2023 Nov;49(11):106977. doi: 10.1016/j.ejso.2023.07.003. Epub 2023 Jul 4. PubMed PMID: 37481390.
Kurz A, Krahl D, Kutzner H, Barnhill R, Perasole A, Figueras MTF, Ferrara G, Braun SA, Starz H, Llamas-Velasco M, Utikal JS, Fröhling S, von Kalle C, Kather JN, Schneider L, Brinker TJ. A 3-dimensional histology computer model of malignant melanoma and its implications for digital pathology. Eur J Cancer. 2023 Nov;193:113294. doi: 10.1016/j.ejca.2023.113294. Epub 2023 Aug 18. PubMed PMID: 37690178.
Mock A, Teleanu MV, Kreutzfeldt S, Heilig CE, Hüllein J, Möhrmann L, Jahn A, Hanf D, Kerle IA, Singh HM, Hutter B, Uhrig S, Fröhlich M, Neumann O, Hartig A, Brückmann S, Hirsch S, Grund K, Dikow N, Lipka DB, Renner M, Bhatti IA, Apostolidis L, Schlenk RF, Schaaf CP, Stenzinger A, Schröck E, Hübschmann D, Heining C, Horak P, Glimm H, Fröhling S. NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. NPJ Precis Oncol. 2023 Oct 26;7(1):109. doi: 10.1038/s41698-023-00458-w. PubMed PMID: 37884744; PubMed Central PMCID: PMC10603123.
Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez L, Pozsgai MJ, McNeely KE, Ha T, Venugopal P, Arts P, King-Smith SL, Cheah J, Armstrong M, Wang P, Bödör C, Cantor AB, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fröhling S, Rio-Machin A, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Kim E, Sood R, Hsu AP, Holland SM, Phillips K, Poplawski NK, Babic M, Wei AH, Forsyth C, Mar Fan H, Lewis ID, Cooney J, Susman R, Fox LC, Blombery P, Singhal D, Hiwase D, Phipson B, Schreiber AW, Hahn CN, Scott HS, Liu P, Godley LA, Brown AL. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023 Oct 24;7(20):6092-6107. doi: 10.1182/bloodadvances.2023010045. PubMed PMID: 37406166; PubMed Central PMCID: PMC10582382.
Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, Boerries M, Wolter S, Ball M, Neumann O, Armeanu-Ebinger S, Schroeder C, Matysiak U, Goldschmid H, Schipperges V, Fürstberger A, Allgäuer M, Eberhardt T, Niewöhner J, Blaumeiser A, Ploeger C, Haack TB, Tay TKY, Kelemen O, Pauli T, Kirchner M, Kluck K, Ott A, Renner M, Admard J, Gschwind A, Lassmann S, Kestler H, Fend F, Illert AL, Werner M, Möller P, Seufferlein TTW, Malek N, Schirmacher P, Fröhling S, Kazdal D, Budczies J, Stenzinger A. Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients. NPJ Precis Oncol. 2023 Oct 20;7(1):106. doi: 10.1038/s41698-023-00457-x. PMID: 37864096; PMCID: PMC10589320.
Lauinger M, Christen D, Klar RFU, Roubaty C, Heilig CE, Stumpe M, Knox JJ, Radulovich N, Tamblyn L, Xie IY, Horak P, Forschner A, Bitzer M, Wittel UA, Boerries M, Ball CR, Heining C, Glimm H, Fröhlich M, Hübschmann D, Gallinger S, Fritsch R, Fröhling S, O'Kane GM, Dengjel J, Brummer T. BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability. Sci Adv. 2023 Sep;9(35):eade7486. doi: 10.1126/sciadv.ade7486. Epub 2023 Sep 1. PMID: 37656784.
Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C, Ploeger C, Lassen U, Le Tourneau C, Lehtiö J, Ott PA, von Deimling A, Fröhling S, Voest E, Klauschen F, Dienstmann R, Alshibany A, Siu LL, Stenzinger A. Precision cancer medicine: Concepts, current practice, and future developments. J Intern Med. 2023 Oct;294(4):455-481. doi: 10.1111/joim.13709. Epub 2023 Aug 28. Review. PubMed PMID: 37641393.
Wurm AA, Brilloff S, Kolovich S, Schäfer S, Rahimian E, Kufrin V, Bill M, Carrero ZI, Drukewitz S, Krüger A, Hüther M, Uhrig S, Oster S, Westphal D, Meier F, Pfütze K, Hübschmann D, Horak P, Kreutzfeldt S, Richter D, Schröck E, Baretton G, Heining C, Möhrmann L, Fröhling S, Ball CR, Glimm H. Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. Cell Rep Med. 2023 Sep 12;:101200. doi: 10.1016/j.xcrm.2023.101200. [Epub ahead of print] PubMed PMID: 37734378.
de Bortoli T, Benary M, Horak P, Lamping M, Stintzing S, Tinhofer I, Leyvraz S, Schäfer R, Klauschen F, Keller U, Stenzinger A, Fröhling S, Kurzrock R, Keilholz U, Rieke DT, Jelas I. Tumour mutational burden and survival with molecularly matched therapy. Eur J Cancer. 2023 Sep;190:112925. doi: 10.1016/j.ejca.2023.05.013. PubMed PMID: 37544709.
Tretter C, de Andrade Krätzig N, Pecoraro M, Lange S, Seifert P, von Frankenberg C, Untch J, Zuleger G, Wilhelm M, Zolg DP, Dreyer FS, Bräunlein E, Engleitner T, Uhrig S, Boxberg M, Steiger K, Slotta-Huspenina J, Ochsenreither S, von Bubnoff N, Bauer S, Boerries M, Jost PJ, Schenck K, Dresing I, Bassermann F, Friess H, Reim D, Grützmann K, Pfütze K, Klink B, Schröck E, Haller B, Kuster B, Mann M, Weichert W, Fröhling S, Rad R, Hiltensperger M, Krackhardt AM. Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification. Nat Commun. 2023 Aug 2;14(1):4632. doi: 10.1038/s41467-023-39570-7. PubMed PMID: 37532709; PubMed Central PMCID: PMC10397250.
Stenzinger A, Moltzen EK, Winkler E, Molnar-Gabor F, Malek N, Costescu A, Jensen BN, Nowak F, Pinto C, Ottersen OP, Schirmacher P, Nordborg J, Seufferlein T, Fröhling S, Edsjö A, Garcia-Foncillas J, Normanno N, Lundgren B, Friedman M, Bolanos N, Tatton-Brown K, Hill S, Rosenquist R. Implementation of precision medicine in healthcare-A European perspective. J Intern Med. 2023 Jul 16;. doi: 10.1111/joim.13698. [Epub ahead of print] Review. PubMed PMID: 37455247.
Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez LA, Pozsgai MJ, McNeely KE, Ha TT, Venugopal P, Arts P, King-Smith S, Cheah JJ, Armstrong M, Wang P, Bödör C, Cantor AB, Cazzola M, Degelman ES, DiNardo CD, Duployez N, Favier R, Fröhling S, Rio-Machin A, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Georges N, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff HY, Ripperger T, Schulte RR, Tawana K, Velloso E, Benedict Y, Kim EMK, Sood R, Hsu AP, Holland SM, Phillips K, Poplawski N, Babic M, Wei AH, Forsyth CJ, Mar Fan H, Lewis I, Cooney JP, Susman R, Fox LC, Blombery P, Singhal D, Hiwase DK, Phipson B, Schreiber AW, Hahn CN, Scott HS, Liu PP, Godley LA, Brown AL. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants. Blood Adv. 2023 Jul 5;. doi: 10.1182/bloodadvances.2023010045. [Epub ahead of print] PubMed PMID: 37406166.
Teleanu MV, Fuss CT, Paramasivam N, Pirmann S, Mock A, Terkamp C, Kircher S, Landwehr LS, Lenschow C, Schlegel N, Stenzinger A, Jahn A, Fassnacht M, Glimm H, Hübschmann D, Fröhling S, Kroiss M. Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling. Mol Oncol. 2023 Jul;17(7):1343-1355. doi: 10.1002/1878-0261.13398. Epub 2023 Apr 11. PubMed PMID: 36808802.
Wessels F, Schmitt M, Krieghoff-Henning E, Nientiedt M, Waldbillig F, Neuberger M, Kriegmair MC, Kowalewski KF, Worst TS, Steeg M, Popovic ZV, Gaiser T, von Kalle C, Utikal JS, Fröhling S, Michel MS, Nuhn P, Brinker TJ. A self-supervised vision transformer to predict survival from histopathology in renal cell carcinoma. World J Urol. 2023 Jun 29;. doi: 10.1007/s00345-023-04489-7. [Epub ahead of print] PubMed PMID: 37382622.
Menzel M, Endris V, Schwab C, Kluck K, Neumann O, Beck S, Ball M, Schaaf C, Fröhling S, Lichtner P, Schirmacher P, Kazdal D, Stenzinger A, Budczies J. Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD). Transl Oncol. 2023 Jun 14;35:101706. doi: 10.1016/j.tranon.2023.101706. [Epub ahead of print] PubMed PMID: 37327584.
Remde H, Schmidt-Pennington L, Reuter M, Landwehr LS, Jensen M, Lahner H, Kimpel O, Altieri B, Laubner K, Schreiner J, Bojunga J, Kircher S, Kunze CA, Pohrt A, Teleanu MV, Hübschmann D, Stenzinger A, Glimm H, Fröhling S, Fassnacht M, Mai K, Kroiss M. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. Eur J Endocrinol. 2023 Jun 7;188(6):485-493. doi: 10.1093/ejendo/lvad054. PubMed PMID: 37260092.
Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek NP. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med. 2023 Jun 6;. doi: 10.1038/s41591-023-02354-z. [Epub ahead of print] PubMed PMID: 37280276.
Remde H, Schmidt-Pennington L, Reuter M, Landwehr LS, Jensen M, Lahner H, Kimpel O, Altieri B, Laubner K, Schreiner J, Bojunga J, Kircher S, Kunze CA, Pohrt A, Teleanu MV, Hübschmann D, Stenzinger A, Glimm H, Fröhling S, Fassnacht M, Mai K, Kroiss M. Outcome of Immunotherapy in Adrenocortical Carcinoma - A retrospective cohort study. Eur J Endocrinol. 2023 Jun 1;. doi: 10.1093/ejendo/lvad054. [Epub ahead of print] PubMed PMID: 37260092.
Gaidzik VI, Paschka P, Schlenk RF, Weber D, Fröhling S, Krämer A, Wäsch R, Westermann J, Mayer K, de Wit M, Fiedler W, Benner A, Heuser M, Thol F, Döhner K, Ganser A, Döhner H. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial. Hemasphere. 2023 May;7(5):e877. doi: 10.1097/HS9.0000000000000877. eCollection 2023 May. PubMed PMID: 37101762; PubMed Central PMCID: PMC10125418.
Weichenhan D, Riedel A, Meinen C, Basic A, Toth R, Bähr M, Lutsik P, Hey J, Sollier E, Toprak UH, Kelekçi S, Lin YY, Hakobyan M, Touzart A, Goyal A, Wierzbinska JA, Schlesner M, Westermann F, Lipka DB, Plass C. Translocation t(6;7) in AML-M4 cell line GDM-1 results in MNX1 activation through enhancer-hijacking. Leukemia. 2023 May;37(5):1147-1150. doi: 10.1038/s41375-023-01865-5. Epub 2023 Mar 22. PubMed PMID: 36949154; PubMed Central PMCID: PMC10169647.
Rausch T, Snajder R, Leger A, Simovic M, Giurgiu M, Villacorta L, Henssen AG, Fröhling S, Stegle O, Birney E, Bonder MJ, Ernst A, Korbel JO. Long-read sequencing of diagnosis and post-therapy medulloblastoma reveals complex rearrangement patterns and epigenetic signatures. Cell Genom. 2023 Apr 12;3(4):100281. doi: 10.1016/j.xgen.2023.100281. eCollection 2023 Apr 12. PubMed PMID: 37082141; PubMed Central PMCID: PMC10112291.
Hey J, Halperin C, Hartmann M, Mayer S, Schönung M, Lipka DB, Scherz-Shouval R, Plass C. DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors and prognostic value relevant to triple-negative breast cancer patients. Int J Cancer. 2023 Mar 15;152(6):1226-1242. doi: 10.1002/ijc.34364. Epub 2022 Dec 9. PubMed PMID: 36408934.
Kreutzfeldt S, Horak P, Hübschmann D, Knurr A, Fröhling S. National Center for Tumor Diseases Precision Oncology Thesaurus for Drugs: A Curated Database for Drugs, Drug Classes, and Drug Targets in Precision Cancer Medicine. JCO Clin Cancer Inform. 2023 Mar;7:e2200147. doi: 10.1200/CCI.22.00147. PubMed PMID: 36888935.
Manoochehri M, Borhani N, Gerhäuser C, Assenov Y, Schönung M, Hielscher T, Christensen BC, Lee MK, Gröne HJ, Lipka DB, Brüning T, Brauch H, Ko YD, Hamann U. DNA methylation biomarkers for noninvasive detection of triple-negative breast cancer using liquid biopsy. Int J Cancer. 2023 Mar 1;152(5):1025-1035. doi: 10.1002/ijc.34337. Epub 2022 Nov 8. Review. PubMed PMID: 36305646.
Christopoulos P, Schlenk R, Kazdal D, Blasi M, Lennerz J, Shah R, Budczies J, Malek N, Fröhling S, Rosenquist R, Schirmacher P, Bozorgmehr F, Kuon J, Reck M, Thomas M, Stenzinger A. Real-world data for precision cancer medicine-A European perspective. Genes Chromosomes Cancer. 2023 Feb 28;. doi: 10.1002/gcc.23135. [Epub ahead of print] PubMed PMID: 36852573.
Teleanu MV, Fuss CT, Paramasivam N, Pirmann S, Mock A, Terkamp C, Kircher S, Landwehr LS, Lenschow C, Schlegel N, Stenzinger A, Jahn A, Fassnacht M, Glimm H, Hübschmann D, Fröhling S, Kroiss M. Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling. Mol Oncol. 2023 Feb 19;. doi: 10.1002/1878-0261.13398. [Epub ahead of print] PubMed PMID: 36808802.
Mock A, Braun M, Scholl C, Fröhling S, Erkut C. Transcriptome profiling for precision cancer medicine using shallow nanopore cDNA sequencing. Sci Rep. 2023 Feb 9;13(1):2378. doi: 10.1038/s41598-023-29550-8. PubMed PMID: 36759549; PubMed Central PMCID: PMC9911782.
Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. J Cancer Res Clin Oncol. 2023 Feb;149(2):913-919. doi: 10.1007/s00432-022-04407-1. Epub 2022 Oct 14. PubMed PMID: 36241862; PubMed Central PMCID: PMC9568964.
Rothermundt C, Andreou D, Blay JY, Brodowicz T, Desar IME, Dileo P, Gelderblom H, Haas R, Jakob J, Jones RL, Judson I, Kunz WG, Liegl-Atzwanger B, Lindner LH, Messiou C, Miah AB, Reichardt P, Szkandera J, van der Graaf WTA, van Houdt WJ, Wardelmann E, Hofer S. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. Eur J Cancer. 2023 Feb;180:158-179. doi: 10.1016/j.ejca.2022.11.008. Epub 2022 Nov 16. PubMed PMID: 36599184.
Thatikonda V, Islam SMA, Autry RJ, Jones BC, Gröbner SN, Warsow G, Hutter B, Huebschmann D, Fröhling S, Kool M, Blattner-Johnson M, Jones DTW, Alexandrov LB, Pfister SM, Jäger N. Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nat Cancer. 2023 Feb;4(2):276-289. doi: 10.1038/s43018-022-00509-4. Epub 2023 Jan 26. PubMed PMID: 36702933; PubMed Central PMCID: PMC9970869.
Schönung M, Hartmann M, Krämer S, Stäble S, Hakobyan M, Kleinert E, Aurich T, Cobanoglu D, Heidel FH, Fröhling S, Milsom MD, Schlesner M, Lutsik P, Lipka DB. Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis. Exp Hematol. 2023 Jan;117:24-42.e7. doi: 10.1016/j.exphem.2022.11.001. Epub 2022 Nov 8. PubMed PMID: 36368558.
Wahida A, Buschhorn L, Fröhling S, Jost PJ, Schneeweiss A, Lichter P, Kurzrock R. The coming decade in precision oncology: six riddles. Nat Rev Cancer. 2023 Jan;23(1):43-54. doi: 10.1038/s41568-022-00529-3. Epub 2022 Nov 24. Review. PubMed PMID: 36434139.
Morfouace M, Horak P, Kreutzfeldt S, Stevovic A, de Rojas T, Denisova E, Hutter B, Bautista F, Oliveira J, Defachelles AS, White J, Kasper B, Preusser M, Golfinopoulos V, Pfister S, Van der Graaf W, Wardelmann E, Shenjere P, Fröhling S, McCabe MG. Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study. Eur J Cancer. 2023 Jan;178:216-226. doi: 10.1016/j.ejca.2022.10.020. Epub 2022 Nov 5. PMID: 36470093.
Krysiak K, Danos AM, Saliba J, McMichael JF, Coffman AC, Kiwala S, Barnell EK, Sheta L, Grisdale CJ, Kujan L, Pema S, Lever J, Ridd S, Spies NC, Andric V, Chiorean A, Rieke DT, Clark KA, Reisle C, Venigalla AC, Evans M, Jani P, Takahashi H, Suda A, Horak P, Ritter DI, Zhou X, Ainscough BJ, Delong S, Kesserwan C, Lamping M, Shen H, Marr AR, Hoang MH, Singhal K, Khanfar M, Li BV, Lin WH, Terraf P, Corson LB, Salama Y, Campbell KM, Farncombe KM, Ji J, Zhao X, Xu X, Kanagal-Shamanna R, King I, Cotto KC, Skidmore ZL, Walker JR, Zhang J, Milosavljevic A, Patel RY, Giles RH, Kim RH, Schriml LM, Mardis ER, Jones SJM, Raca G, Rao S, Madhavan S, Wagner AH, Griffith M, Griffith OL. CIViCdb 2022: Evolution of an open-access cancer variant interpretation knowledgebase. Nucleic Acids Res. 2023 Jan 6;51(D1):D1230-D1241. doi: 10.1093/nar/gkac979. PMID: 36373660; PMCID: PMC9825608.

Hoffmeister-Wittmann P, Mock A, Nichetti F, Korell F, Heilig CE, Scherr AL, Günther M, Albrecht T, Kelmendi E, Xu K, Nader L, Kessler A, Schmitt N, Fritzsche S, Weiler S, Sobol B, Stenzinger A, Boeck S, Westphalen CB, Schulze-Osthoff K, Trojan J, Kindler T, Weichert W, Spiekermann K, Bitzer M, Folprecht G, Illert AL, Boerries M, Klauschen F, Ochsenreither S, Siveke J, Bauer S, Glimm H, Brors B, Hüllein J, Hübschmann D, Uhrig S, Horak P, Kreutzfeldt S, Banales JM, Springfeld C, Jäger D, Schirmacher P, Roessler S, Ormanns S, Goeppert B, Fröhling S, Köhler BC. Bcl-x_L as prognostic marker and potential therapeutic target in cholangiocarcinoma. Liver Int. 2022 Dec;42(12):2855-2870. doi: 10.1111/liv.15392. Epub 2022 Sep 14. PubMed PMID: 35983950.
Dietlein N, Wang X, Metz J, Disson O, Shang F, Beyersdörffer C, Rodríguez Correa E, Lipka DB, Begus-Nahrmann Y, Kosinsky RL, Johnsen SA, Lecuit M, Höfer T, Rodewald HR. Usp22 is an intracellular regulator of systemic emergency hematopoiesis. Sci Immunol. 2022 Dec 16;7(78):eabq2061. doi: 10.1126/sciimmunol.abq2061. Epub 2022 Dec 9. PubMed PMID: 36490327.
Fröhling S. Toward defining the clinically actionable genome of metastatic breast cancer. Med. 2022 Dec 9;3(12):818-819. doi: 10.1016/j.medj.2022.11.004. PubMed PMID: 36495861.
Hoffmeister-Wittmann P, Mock A, Nichetti F, Korell F, Heilig CE, Scherr AL, Günther M, Albrecht T, Kelmendi E, Xu K, Nader L, Kessler A, Schmitt N, Fritzsche S, Weiler S, Sobol B, Stenzinger A, Boeck S, Westphalen CB, Schulze-Osthoff K, Trojan J, Kindler T, Weichert W, Spiekermann K, Bitzer M, Folprecht G, Illert AL, Boerries M, Klauschen F, Ochsenreither S, Siveke J, Bauer S, Glimm H, Brors B, Hüllein J, Hübschmann D, Uhrig S, Horak P, Kreutzfeldt S, Banales JM, Springfeld C, Jäger D, Schirmacher P, Roessler S, Ormanns S, Goeppert B, Fröhling S, Köhler BC. Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma. Liver Int. 2022 Dec;42(12):2855-2870. doi: 10.1111/liv.15392. Epub 2022 Sep 14. PMID: 35983950.
Cuppen E, Elemento O, Rosenquist R, Nikic S, IJzerman M, Zaleski ID, Frederix G, Levin LÅ, Mullighan CG, Buettner R, Pugh TJ, Grimmond S, Caldas C, Andre F, Custers I, Campo E, van Snellenberg H, Schuh A, Nakagawa H, von Kalle C, Haferlach T, Fröhling S, Jobanputra V. Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care. JCO Precis Oncol. 2022 Dec;6:e2200245. doi: 10.1200/PO.22.00245. Review. PubMed PMID: 36480778; PubMed Central PMCID: PMC10166391.
Steinbach C, Merchant A, Zaharie AT, Horak P, Marhold M, Krainer M. Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies. Cancers (Basel). 2022 Nov 21;14(22):5719. doi: 10.3390/cancers14225719. PMID: 36428811; PMCID: PMC9688882.
Neumann O, Burn TC, Allgäuer M, Ball M, Kirchner M, Albrecht T, Volckmar AL, Beck S, Endris V, Goldschmid H, Lehmann U, Seker-Cin H, Uhrig S, Roessler S, Budczies J, Fröhling S, Longerich T, Wagner AH, Vogel A, Schirmacher P, Stenzinger A, Kazdal D. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer. 2022 Nov;127(8):1540-1549. doi: 10.1038/s41416-022-01908-1. Epub 2022 Jul 23. PubMed PMID: 35871236; PubMed Central PMCID: PMC9553883.
Jahn A, Rump A, Widmann TJ, Heining C, Horak P, Hutter B, Paramasivam N, Uhrig S, Gieldon L, Drukewitz S, Kübler A, Bermudez M, Hackmann K, Porrmann J, Wagner J, Arlt M, Franke M, Fischer J, Kowalzyk Z, William D, Weth V, Oster S, Fröhlich M, Hüllein J, Valle González C, Kreutzfeldt S, Mock A, Heilig CE, Lipka DB, Möhrmann L, Hanf D, Oleś M, Teleanu V, Allgäuer M, Ruhnke L, Kutz O, Knurr A, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Metzeler KH, Bitzer M, Schulze-Osthoff K, von Kalle C, Brors B, Stenzinger A, Weichert W, Hübschmann D, Fröhling S, Glimm H, Schröck E, Klink B. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Ann Oncol. 2022 Nov;33(11):1186-1199. doi: 10.1016/j.annonc.2022.07.008. Epub 2022 Aug 18. PubMed PMID: 35988656.
Rieke DT, de Bortoli T, Horak P, Lamping M, Benary M, Jelas I, Rüter G, Berger J, Zettwitz M, Kagelmann N, Kind A, Fabian F, Beule D, Glimm H, Brors B, Stenzinger A, Fröhling S, Keilholz U. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards. BMC Med. 2022 Oct 24;20(1):367. doi: 10.1186/s12916-022-02560-5. PMID: 36274133; PMCID: PMC9590222.
Wessels F, Kuntz S, Krieghoff-Henning E, Schmitt M, Braun V, Worst TS, Neuberger M, Steeg M, Gaiser T, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Artificial intelligence to predict oncological outcome directly from hematoxylin and eosin-stained slides in urology. Minerva Urol Nephrol. 2022 Oct;74(5):538-550. doi: 10.23736/S2724-6051.22.04758-9. Epub 2022 Mar 11. PubMed PMID: 35274903.
Kreutzfeldt S, Knurr A, Hübschmann D, Horak P, Fröhling S. NCT Precision Oncology Thesaurus Drugs – a Curated Database for Drugs, Drug Classes, and Drug Targets in Precision Cancer Medicine. medRxiv; 2022 September 23. doi: 10.1101/2022.09.11.22279783. PPR: PPR545867.
Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavelier L, Schirmacher P, Malek N, Rosenquist R. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2022 Sep;84:242-254. doi: 10.1016/j.semcancer.2021.05.026. Epub 2021 May 24. Review. PubMed PMID: 34033893.
Rosenquist R, Fröhling S, Stamatopoulos K. Precision medicine in cancer: A paradigm shift. Semin Cancer Biol. 2022 Sep;84:1-2. doi: 10.1016/j.semcancer.2022.05.008. Epub 2022 May 18. PubMed PMID: 35597437.
Weichenhan D, Lipka DB, Lutsik P, Goyal A, Plass C. Epigenomic technologies for precision oncology. Semin Cancer Biol. 2022 Sep;84:60-68. doi: 10.1016/j.semcancer.2020.08.004. Epub 2020 Aug 18. Review. PubMed PMID: 32822861.
Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, Bauer S, Siveke JT, Hamacher R, Folprecht G, Richter S, Schröck E, Brandts CH, Ahrens M, Hohenberger P, Egerer G, Kindler T, Boerries M, Illert AL, von Bubnoff N, Apostolidis L, Jost PJ, Westphalen CB, Weichert W, Keilholz U, Klauschen F, Beck K, Winter U, Richter D, Möhrmann L, Bitzer M, Schulze-Osthoff K, Brors B, Mechtersheimer G, Kreutzfeldt S, Heining C, Lipka DB, Stenzinger A, Schlenk RF, Horak P, Glimm H, Hübschmann D, Fröhling S. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022 Sep;172:107-118. doi: 10.1016/j.ejca.2022.05.025. Epub 2022 Jun 25. PubMed PMID: 35763870.
Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep;24(9):1991. doi: 10.1016/j.gim.2022.07.001. Erratum for: Genet Med. 2022 May;24(5):986-998. PMID: 36063163.
Horak P, Chakravarty D, Sonkin D. Response to Mehta et al. Genet Med. 2022 Sep;24(9):1989-1990. doi: 10.1016/j.gim.2022.05.018. Epub 2022 Jul 7. PMID: 35796744.
van der Graaf WTA, Tesselaar MET, McVeigh TP, Oyen WJG, Fröhling S. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. Semin Cancer Biol. 2022 Sep;84:228-241. doi: 10.1016/j.semcancer.2022.05.011. Epub 2022 May 25. Review. PubMed PMID: 35643220.
Maron RC, Hekler A, Haggenmüller S, von Kalle C, Utikal JS, Müller V, Gaiser M, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Lipka DB, Krieghoff-Henning E, Brinker TJ. Model soups improve performance of dermoscopic skin cancer classifiers. Eur J Cancer. 2022 Sep;173:307-316. doi: 10.1016/j.ejca.2022.07.002. Epub 2022 Aug 13. PubMed PMID: 35973360.
Meier R, Greve G, Zimmer D, Bresser H, Berberich B, Langova R, Stomper J, Rubarth A, Feuerbach L, Lipka DB, Hey J, Grüning B, Brors B, Duyster J, Plass C, Becker H, Lübbert M. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation. Blood Cancer J. 2022 Aug 22;12(8):122. doi: 10.1038/s41408-022-00715-4. PubMed PMID: 35995769; PubMed Central PMCID: PMC9395383.
Bogeska R, Mikecin AM, Kaschutnig P, Fawaz M, Büchler-Schäff M, Le D, Ganuza M, Vollmer A, Paffenholz SV, Asada N, Rodriguez-Correa E, Frauhammer F, Buettner F, Ball M, Knoch J, Stäble S, Walter D, Petri A, Carreño-Gonzalez MJ, Wagner V, Brors B, Haas S, Lipka DB, Essers MAG, Weru V, Holland-Letz T, Mallm JP, Rippe K, Krämer S, Schlesner M, McKinney Freeman S, Florian MC, King KY, Frenette PS, Rieger MA, Milsom MD. Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. Cell Stem Cell. 2022 Aug 4;29(8):1273-1284.e8. doi: 10.1016/j.stem.2022.06.012. Epub 2022 Jul 19. PubMed PMID: 35858618; PubMed Central PMCID: PMC9357150.
Möhrmann L, Werner M, Oleś M, Mock A, Uhrig S, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam N, Richter D, Beck K, Winter U, Pfütze K, Heilig CE, Teleanu V, Lipka DB, Zapatka M, Hanf D, List C, Allgäuer M, Penzel R, Rüter G, Jelas I, Hamacher R, Falkenhorst J, Wagner S, Brandts CH, Boerries M, Illert AL, Metzeler KH, Westphalen CB, Desuki A, Kindler T, Folprecht G, Weichert W, Brors B, Stenzinger A, Schröck E, Hübschmann D, Horak P, Heining C, Fröhling S, Glimm H. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nat Commun. 2022 Aug 2;13(1):4485. doi: 10.1038/s41467-022-31866-4. PubMed PMID: 35918329; PubMed Central PMCID: PMC9346116.
Harrison C, Heidel FH, Vannucchi AM, Kiladjian JJ, Hayat A, Passamonti F, Conneally E, Kindler T, Martino B, Lipka DB, Stefanelli T, Roussou P, Germano D, Ewan J, Ribrag V. A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis. Hemasphere. 2022 Aug;6(8):e757. doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug. PubMed PMID: 35935608; PubMed Central PMCID: PMC9348858.
Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hüllein J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. Mol Oncol. 2022 Jul;16(14):2733-2746. doi: 10.1002/1878-0261.13256. Epub 2022 Jun 13. PubMed PMID: 35621918; PubMed Central PMCID: PMC9297767.
Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, Bauer S, Siveke JT, Hamacher R, Folprecht G, Richter S, Schröck E, Brandts CH, Ahrens M, Hohenberger P, Egerer G, Kindler T, Boerries M, Illert AL, von Bubnoff N, Apostolidis L, Jost PJ, Westphalen CB, Weichert W, Keilholz U, Klauschen F, Beck K, Winter U, Richter D, Möhrmann L, Bitzer M, Schulze-Osthoff K, Brors B, Mechtersheimer G, Kreutzfeldt S, Heining C, Lipka DB, Stenzinger A, Schlenk RF, Horak P, Glimm H, Hübschmann D, Fröhling S. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022 Jun 25;172:107-118. doi: 10.1016/j.ejca.2022.05.025. [Epub ahead of print] PubMed PMID: 35763870.
Frank L, Rademacher A, Mücke N, Tirier SM, Koeleman E, Knotz C, Schumacher S, Stainczyk SA, Westermann F, Fröhling S, Chudasama P, Rippe K. ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Res. 2022 Jun 24;50(11):e61. doi: 10.1093/nar/gkac113. PubMed PMID: 35188570.
Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). NPJ Precis Oncol. 2022 Jun 9;6(1):36. doi: 10.1038/s41698-022-00276-6. PubMed PMID: 35681079.
Reissig TM, Uhrig S, Jost PJ, Luchini C, Vicentini C, Liffers ST, Allgäuer M, Adsay V, Scarpa A, Lawlor RT, Fröhling S, Stenzinger A, Klöppel G, Schildhaus HU, Siveke JT. MCL1 as putative target in pancreatoblastoma. Virchows Arch. 2022 Jun 7;. doi: 10.1007/s00428-022-03349-w. [Epub ahead of print] PubMed PMID: 35668118.
Horak P, Leichsenring J, Goldschmid H, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Gieldon L, Allgäuer M, Volckmar AL, Dikow N, Renner M, Kirchner M, Penzel R, Ploeger C, Brandt R, Seker-Cin H, Budczies J, Heilig CE, Neumann O, Schaaf CP, Schirmacher P, Fröhling S, Stenzinger A. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes Cancer. 2022 Jun;61(6):303-313. doi: 10.1002/gcc.22987. Epub 2021 Aug 9. Review. PubMed PMID: 34331337.
Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hüllein J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. Mol Oncol. 2022 May 27;. doi: 10.1002/1878-0261.13256. [Epub ahead of print] PubMed PMID: 35621918.
van der Graaf WTA, Tesselaar MET, McVeigh TP, Oyen WJG, Fröhling S. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. Semin Cancer Biol. 2022 May 25;. doi: 10.1016/j.semcancer.2022.05.011. [Epub ahead of print] Review. PubMed PMID: 35643220.
Wästerlid T, Cavelier L, Haferlach C, Konopleva M, Fröhling S, Östling P, Bullinger L, Fioretos T, Smedby KE. Application of precision medicine in clinical routine in haematology-Challenges and opportunities. J Intern Med. 2022 May 22;. doi: 10.1111/joim.13508. [Epub ahead of print] Review. PubMed PMID: 35599019.
Rosenquist R, Fröhling S, Stamatopoulos K. Precision medicine in cancer: A paradigm shift. Semin Cancer Biol. 2022 May 18;. doi: 10.1016/j.semcancer.2022.05.008. [Epub ahead of print] PubMed PMID: 35597437.
Schedel A, Friedrich UA, Morcos MNF, Wagener R, Mehtonen J, Watrin T, Saitta C, Brozou T, Michler P, Walter C, Försti A, Baksi A, Menzel M, Horak P, Paramasivam N, Fazio G, Autry RJ, Fröhling S, Suttorp M, Gertzen C, Gohlke H, Bhatia S, Wadt K, Schmiegelow K, Dugas M, Richter D, Glimm H, Heinäniemi M, Jessberger R, Cazzaniga G, Borkhardt A, Hauer J, Auer F. Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma. Int J Mol Sci. 2022 May 5;23(9). doi: 10.3390/ijms23095174. PubMed PMID: 35563565; PubMed Central PMCID: PMC9106003.
Hauser K, Kurz A, Haggenmüller S, Maron RC, von Kalle C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Kutzner H, Berking C, Heppt MV, Erdmann M, Haferkamp S, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Lipka DB, Hekler A, Krieghoff-Henning E, Brinker TJ. Explainable artificial intelligence in skin cancer recognition: A systematic review. Eur J Cancer. 2022 May;167:54-69. doi: 10.1016/j.ejca.2022.02.025. Epub 2022 Apr 5. Review. PubMed PMID: 35390650.
Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May;24(5):986-998. doi: 10.1016/j.gim.2022.01.001. Epub 2022 Jan 29. Erratum in: Genet Med. 2022 Sep;24(9):1991. PMID: 35101336; PMCID: PMC9081216.
Krysiak K, Danos AM, Kiwala S, McMichael JF, Coffman AC, Barnell EK, Sheta L, Saliba J, Grisdale CJ, Kujan L, Pema S, Lever J, Spies NC, Chiorean A, Rieke DT, Clark KA, Jani P, Takahashi H, Horak P, Ritter DI, Zhou X, Ainscough BJ, Delong S, Lamping M, Marr AR, Li BV, Lin WH, Terraf P, Salama Y, Campbell KM, Farncombe KM, Ji J, Zhao X, Xu X, Kanagal-Shamanna R, Cotto KC, Skidmore ZL, Walker JR, Zhang J, Milosavljevic A, Patel RY, Giles RH, Kim RH, Schriml LM, Mardis ER, Jones SJM, Raca G, Rao S, Madhavan S, Wagner AH, Griffith OL, Griffith M. A community approach to the cancer-variant-interpretation bottleneck. Nat Cancer. 2022 May;3(5):522-525. doi: 10.1038/s43018-022-00379-w. PMID: 35624339; PMCID: PMC9872366.
Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 May;3(5):649. doi: 10.1038/s43018-022-00378-x. PubMed PMID: 35449310.
Ball M, Christopoulos P, Kirchner M, Allgäuer M, Brandt R, Winter H, Heußel CP, Herth F, Fröhling S, Savai R, Kriegsmann M, Schirmacher P, Peters S, Thomas M, Stenzinger A, Kazdal D. Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report. Cold Spring Harb Mol Case Stud. 2022 Apr;8(3). doi: 10.1101/mcs.a006156. Print 2022 Apr. PubMed PMID: 35058282; PubMed Central PMCID: PMC9059782.
Nitsch L, Jensen P, Yoon H, Koeppel J, Burman SSR, Fischer ES, Scholl C, Fröhling S, Słabicki M. BTB_BCL6 dimers as building blocks for reversible drug-induced protein oligomerization. Cell Rep Methods. 2022 Apr 25;2(4):100193. doi: 10.1016/j.crmeth.2022.100193. eCollection 2022 Apr 25. PubMed PMID: 35497498; PubMed Central PMCID: PMC9046236.
Berthold R, Isfort I, Erkut C, Heinst L, Grünewald I, Wardelmann E, Kindler T, Åman P, Grünewald TGP, Cidre-Aranaz F, Trautmann M, Fröhling S, Scholl C, Hartmann W. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. Oncogenesis. 2022 Apr 22;11(1):20. doi: 10.1038/s41389-022-00394-7. PubMed PMID: 35459264; PubMed Central PMCID: PMC9033823.
Simon M, Mughal SS, Horak P, Uhrig S, Buchloh J, Aybey B, Stenzinger A, Glimm H, Fröhling S, Brors B, Imbusch CD. Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. J Transl Med. 2022 Apr 2;20(1):152. doi: 10.1186/s12967-022-03316-8. PubMed PMID: 35366909; PubMed Central PMCID: PMC8977019.
Wessels F, Kuntz S, Krieghoff-Henning E, Schmitt M, Braun V, Worst TS, Neuberger M, Steeg M, Gaiser T, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Artificial intelligence to predict oncological outcome directly from hematoxylin & eosin-stained slides in urology: a systematic review. Minerva Urol Nephrol. 2022 Mar 11;. doi: 10.23736/S2724-6051.22.04758-9. [Epub ahead of print] PubMed PMID: 35274903.
Maurus K, Kosnopfel C, Kneitz H, Appenzeller S, Schrama D, Glutsch V, Roth S, Gerhard-Hartmann E, Rosenfeldt M, Möhrmann L, Fröhlich M, Hübschmann D, Stenzinger A, Glimm H, Fröhling S, Goebeler M, Rosenwald A, Kutzner H, Schilling B. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway. Br J Dermatol. 2022 Mar;186(3):553-563. doi: 10.1111/bjd.20869. Epub 2021 Dec 21. PubMed PMID: 34726260.
Brinker TJ, Schmitt M, Krieghoff-Henning EI, Barnhill R, Beltraminelli H, Braun SA, Carr R, Fernandez-Figueras MT, Ferrara G, Fraitag S, Gianotti R, Llamas-Velasco M, Müller CSL, Perasole A, Requena L, Sangueza OP, Santonja C, Starz H, Vale E, Weyers W, Hekler A, Kather JN, Fröhling S, Krahl D, Holland-Letz T, Utikal JS, Saggini A, Kutzner H. Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists. J Am Acad Dermatol. 2022 Mar;86(3):640-642. doi: 10.1016/j.jaad.2021.02.009. Epub 2021 Feb 11. PubMed PMID: 33581189.
Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 Feb;3(2):251-261. doi: 10.1038/s43018-022-00332-x. Epub 2022 Feb 24. PubMed PMID: 35221333; PubMed Central PMCID: PMC8882467.
Frank L, Rademacher A, Mücke N, Tirier SM, Koeleman E, Knotz C, Schumacher S, Stainczyk SA, Westermann F, Fröhling S, Chudasama P, Rippe K. ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Res. 2022 Feb 21;. doi: 10.1093/nar/gkac113. [Epub ahead of print] PubMed PMID: 35188570.
Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S. Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]. Eur J Cancer. 2022 Feb;162:245-246. doi: 10.1016/j.ejca.2021.11.014. Epub 2021 Dec 22. PubMed PMID: 34953660.
Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2022 Feb;71(2):251-265. doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14. PubMed PMID: 34125345; PubMed Central PMCID: PMC8783861.
Marhold M, Udovica S, Topakian T, Horak P, Horvat R, Tomasich E, Heller G, Krainer M. MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice. Cancers (Basel). 2022 Jan 31;14(3):749. doi: 10.3390/cancers14030749. PMID: 35159020; PMCID: PMC8833778.
Schneider L, Laiouar-Pedari S, Kuntz S, Krieghoff-Henning E, Hekler A, Kather JN, Gaiser T, Fröhling S, Brinker TJ. Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review. Eur J Cancer. 2022 Jan;160:80-91. doi: 10.1016/j.ejca.2021.10.007. Epub 2021 Nov 19. PubMed PMID: 34810047.
Czeh M, Stäble S, Krämer S, Tepe L, Talyan S, Carrelha J, Meng Y, Heitplatz B, Schwabenland M, Milsom MD, Plass C, Prinz M, Schlesner M, Andrade-Navarro MA, Nerlov C, Jacobsen SEW, Lipka DB, Rosenbauer F. DNMT1 Deficiency Impacts on Plasmacytoid Dendritic Cells in Homeostasis and Autoimmune Disease. J Immunol. 2022 Jan 15;208(2):358-370. doi: 10.4049/jimmunol.2100624. Epub 2021 Dec 13. PubMed PMID: 34903641; PubMed Central PMCID: PMC7612220.

Heilig CE, Horak P, Kreutzfeldt S, Teleanu V, Mock A, Renner M, Bhatti IA, Hutter B, Hüllein J, Fröhlich M, Uhrig S, Süße H, Heiligenthal L, Ochsenreither S, Illert AL, Vogel A, Desuki A, Heinemann V, Heidegger S, Bitzer M, Scheytt M, Brors B, Hübschmann D, Baretton G, Stenzinger A, Steindorf K, Benner A, Jäger D, Heining C, Glimm H, Fröhling S, Schlenk RF. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. ESMO Open. 2021 Dec;6(6):100310. doi: 10.1016/j.esmoop.2021.100310. Epub 2021 Nov 20. PubMed PMID: 34808524; PubMed Central PMCID: PMC8609144.
Horak P, Uhrig S, Witzel M, Gil-Farina I, Hutter B, Rath T, Gieldon L, Balasubramanian GP, Pastor X, Heilig CE, Richter D, Schröck E, Ball CR, Brors B, Braun CJ, Albert MH, Scholl C, von Kalle C, Schmidt M, Fröhling S, Klein C, Glimm H. Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia. 2021 Dec;35(12):3633. doi: 10.1038/s41375-021-01364-5. PubMed PMID: 34785797; PubMed Central PMCID: PMC8632670.
Koelsche C, Benhamida JK, Kommoss FKF, Stichel D, Jones DTW, Pfister SM, Heilig CE, Fröhling S, Stenzinger A, Buslei R, Mentzel T, Baumhoer D, Ladanyi M, Antonescu CR, Flucke U, Gorp JV, Bode-Lesniewska B, Deimling AV, Mechtersheimer G. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. Mod Pathol. 2021 Dec;34(12):2122-2129. doi: 10.1038/s41379-021-00874-y. Epub 2021 Jul 26. PubMed PMID: 34312479; PubMed Central PMCID: PMC8592836.
Faure-Dupuy S, Riedl T, Rolland M, Hizir Z, Reisinger F, Neuhaus K, Schuehle S, Remouchamps C, Gillet N, Schönung M, Stadler M, Wettengel J, Barnault R, Parent R, Schuster LC, Farhat R, Prokosch S, Leuchtenberger C, Öllinger R, Engleitner T, Rippe K, Rad R, Unger K, Tscharahganeh D, Lipka DB, Protzer U, Durantel D, Lucifora J, Dejardin E, Heikenwälder M. Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p. JHEP Rep. 2021 Dec;3(6):100354. doi: 10.1016/j.jhepr.2021.100354. eCollection 2021 Dec. PubMed PMID: 34704004; PubMed Central PMCID: PMC8523871.
Westphal D, Garzarolli M, Sergon M, Horak P, Hutter B, Becker JC, Wiegel M, Maczey E, Blum S, Grosche-Schlee S, Rütten A, Ugurel S, Stenzinger A, Glimm H, Aust D, Baretton G, Beissert S, Fröhling S, Redler S, Surowy H, Meier F. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. Br J Dermatol. 2021 Dec;185(6):1186-1199. doi: 10.1111/bjd.20604. Epub 2021 Aug 18. PubMed PMID: 34185311.
Fröhling S. Interdisciplinary team science to understand and intercept rare cancers. Mol Cell Oncol. 2021;8(6):1997331. doi: 10.1080/23723556.2021.1997331. eCollection 2021. PubMed PMID: 35419478; PubMed Central PMCID: PMC8997247.
Zanetti C, Kumar R, Ender J, Godavarthy PS, Hartmann M, Hey J, Breuer K, Weissenberger ES, Minciacchi VR, Karantanou C, Gu Z, Roberts KG, Metzler M, Stock W, Mullighan CG, Bloomfield CD, Filmann N, Bankov K, Hartmann S, Hasserjian RP, Cousins AF, Halsey C, Plass C, Lipka DB, Krause DS. The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood. 2021 Nov 11;138(19):1870-1884. doi: 10.1182/blood.2021011557. PubMed PMID: 34424946; PubMed Central PMCID: PMC8767790.
Borchert F, Mock A, Tomczak A, Hügel J, Alkarkoukly S, Knurr A, Volckmar AL, Stenzinger A, Schirmacher P, Debus J, Jäger D, Longerich T, Fröhling S, Eils R, Bougatf N, Sax U, Schapranow MP. Knowledge bases and software support for variant interpretation in precision oncology. Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab246. PubMed PMID: 34125166; PubMed Central PMCID: PMC8575010.
Borchert F, Mock A, Tomczak A, Hügel J, Alkarkoukly S, Knurr A, Volckmar AL, Stenzinger A, Schirmacher P, Debus J, Jäger D, Longerich T, Fröhling S, Eils R, Bougatf N, Sax U, Schapranow MP. Knowledge bases and software support for variant interpretation in precision oncology. Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab134. PubMed PMID: 33971666; PubMed Central PMCID: PMC8574624.
Kiehl L, Kuntz S, Höhn J, Jutzi T, Krieghoff-Henning E, Kather JN, Holland-Letz T, Kopp-Schneider A, Chang-Claude J, Brobeil A, von Kalle C, Fröhling S, Alwers E, Brenner H, Hoffmeister M, Brinker TJ. Deep learning can predict lymph node status directly from histology in colorectal cancer. Eur J Cancer. 2021 Nov;157:464-473. doi: 10.1016/j.ejca.2021.08.039. Epub 2021 Oct 11. PubMed PMID: 34649117.
Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Volckmar AL, Renner M, Kirchner M, Heilig CE, Neumann O, Schirmacher P, Fröhling S, Stenzinger A. Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie. Pathologe. 2021 Nov;42(6):602. doi: 10.1007/s00292-021-01002-y. PubMed PMID: 34605937.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, Fröhlich M, Uhrig S, Jahn A, Rump A, Gieldon L, Möhrmann L, Hanf D, Teleanu V, Heilig CE, Lipka DB, Allgäuer M, Ruhnke L, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Spiekermann K, Bitzer M, Schulze-Osthoff K, von Kalle C, Klink B, Brors B, Stenzinger A, Schröck E, Hübschmann D, Weichert W, Glimm H, Fröhling S. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov. 2021 Nov;11(11):2780-2795. doi: 10.1158/2159-8290.CD-21-0126. Epub 2021 Jun 10. PubMed PMID: 34112699.
Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Bödör C, Cantor A, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fröhling S, Fitzgibbon J, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown AL. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 Nov 1;106(11):3004-3007. doi: 10.3324/haematol.2021.278762. PubMed PMID: 34233450; PubMed Central PMCID: PMC8561292.
Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Oct;15(10):2507-2543. doi: 10.1002/1878-0261.13078. Epub 2021 Sep 13. PubMed PMID: 34515408; PubMed Central PMCID: PMC8486569.
Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, Müller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fröhling S, Hauschild A, Kittler H, Brinker TJ. Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. Eur J Cancer. 2021 Oct;156:202-216. doi: 10.1016/j.ejca.2021.06.049. Epub 2021 Sep 8. PubMed PMID: 34509059.
Kirchner M, Kluck K, Brandt R, Volckmar AL, Penzel R, Kazdal D, Endris V, Neumann O, Seker-Cin H, Goldschmid H, Glade J, Allgäuer M, Kriegsmann M, Winter H, Muley T, Perner S, Frost N, Reck M, Fröhling S, Schirmacher P, Thomas M, Budczies J, Christopoulos P, Stenzinger A. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open. 2021 Oct;6(5):100253. doi: 10.1016/j.esmoop.2021.100253. Epub 2021 Sep 3. PubMed PMID: 34487971; PubMed Central PMCID: PMC8426209.
Brinker TJ, Kiehl L, Schmitt M, Jutzi TB, Krieghoff-Henning EI, Krahl D, Kutzner H, Gholam P, Haferkamp S, Klode J, Schadendorf D, Hekler A, Fröhling S, Kather JN, Haggenmüller S, von Kalle C, Heppt M, Hilke F, Ghoreschi K, Tiemann M, Wehkamp U, Hauschild A, Weichenthal M, Utikal JS. Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. Eur J Cancer. 2021 Sep;154:227-234. doi: 10.1016/j.ejca.2021.05.026. Epub 2021 Jul 20. PubMed PMID: 34298373.
Kuntz S, Krieghoff-Henning E, Kather JN, Jutzi T, Höhn J, Kiehl L, Hekler A, Alwers E, von Kalle C, Fröhling S, Utikal JS, Brenner H, Hoffmeister M, Brinker TJ. Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. Eur J Cancer. 2021 Sep;155:200-215. doi: 10.1016/j.ejca.2021.07.012. Epub 2021 Aug 11. PubMed PMID: 34391053.
Schönung M, Hess J, Bawidamann P, Stäble S, Hey J, Langstein J, Assenov Y, Weichenhan D, Lutsik P, Lipka DB. AmpliconDesign - an interactive web server for the design of high-throughput targeted DNA methylation assays. Epigenetics. 2021 Sep;16(9):933-939. doi: 10.1080/15592294.2020.1834921. Epub 2020 Oct 24. PubMed PMID: 33100132; PubMed Central PMCID: PMC8451469.
Maron RC, Schlager JG, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Heppt MV, Berking C, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Krieghoff-Henning E, Hekler A, Fröhling S, Lipka DB, Kather JN, Brinker TJ. A benchmark for neural network robustness in skin cancer classification. Eur J Cancer. 2021 Sep;155:191-199. doi: 10.1016/j.ejca.2021.06.047. Epub 2021 Aug 11. PubMed PMID: 34388516.
Wessels F, Schmitt M, Krieghoff-Henning E, Jutzi T, Worst TS, Waldbillig F, Neuberger M, Maron RC, Steeg M, Gaiser T, Hekler A, Utikal JS, von Kalle C, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Deep learning approach to predict lymph node metastasis directly from primary tumour histology in prostate cancer. BJU Int. 2021 Sep;128(3):352-360. doi: 10.1111/bju.15386. Epub 2021 May 5. PubMed PMID: 33706408.
Willis F, Musa J, Schimmack S, Hinz U, Mechtersheimer G, Uhl M, Schmidt T, Fröhling S, Büchler MW, Schneider M. Outcome after surgical resection of multiple recurrent retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2021 Aug;47(8):2189-2200. doi: 10.1016/j.ejso.2021.04.040. Epub 2021 May 4. PubMed PMID: 33980415.
Moratin J, Mock A, Obradovic S, Metzger K, Flechtenmacher C, Zaoui K, Fröhling S, Jäger D, Krauss J, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C. Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. Front Oncol. 2021;11:712944. doi: 10.3389/fonc.2021.712944. eCollection 2021. PubMed PMID: 34395287; PubMed Central PMCID: PMC8359738.
Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. doi: 10.1182/bloodadvances.2020004144. PubMed PMID: 34297046; PubMed Central PMCID: PMC8341358.
Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Med. 2021 Jul 16;13(1):116. doi: 10.1186/s13073-021-00926-7. PubMed PMID: 34271981; PubMed Central PMCID: PMC8283888.
Höhn J, Hekler A, Krieghoff-Henning E, Kather JN, Utikal JS, Meier F, Gellrich FF, Hauschild A, French L, Schlager JG, Ghoreschi K, Wilhelm T, Kutzner H, Heppt M, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Maron RC, Schmitt M, Jutzi T, Fröhling S, Lipka DB, Brinker TJ. Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. J Med Internet Res. 2021 Jul 2;23(7):e20708. doi: 10.2196/20708. Review. PubMed PMID: 34255646; PubMed Central PMCID: PMC8285747.
Krysiak K, Danos AM, Kiwala S, McMichael JF, Coffman AC, Barnell EK, Sheta L, Saliba J, Grisdale CJ, Kujan L, Pema S, Lever J, Spies NC, Chiorean A, Griffith M, Horak P, et al. Evolution of the open-access CIViC knowledgebase is driven by the needs of the cancer variant interpretation community. bioRxiv; 2021 June 14. doi: 10.1101/2021.06.13.448171. PPR: PPR356294.
Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Volckmar AL, Renner M, Kirchner M, Heilig CE, Neumann O, Schirmacher P, Fröhling S, Stenzinger A. [Variant interpretation in molecular pathology and oncology : An introduction]. Pathologe. 2021 Jul;42(4):369-379. doi: 10.1007/s00292-021-00938-5. Epub 2021 May 3. Review. PubMed PMID: 33938987.
Bertero L, Righi L, Collemi G, Koelsche C, Hou Y, Stichel D, Schrimpf D, Flucke U, Petersen I, Vokuhl C, Fröhling S, Bironzo P, Scagliotti GV, Cassoni P, Papotti M, von Deimling A. DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. J Mol Diagn. 2021 Jul;23(7):834-846. doi: 10.1016/j.jmoldx.2021.04.002. Epub 2021 Apr 20. PubMed PMID: 33887463.
Mock A, Plath M, Moratin J, Tapken MJ, Jäger D, Krauss J, Fröhling S, Hess J, Zaoui K. EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers. Front Oncol. 2021;11:678966. doi: 10.3389/fonc.2021.678966. eCollection 2021. PubMed PMID: 34178665; PubMed Central PMCID: PMC8226088.
Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavelier L, Schirmacher P, Malek N, Rosenquist R. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2021 May 24;. doi: 10.1016/j.semcancer.2021.05.026. [Epub ahead of print] PubMed PMID: 34033893.
Simon M, Mughal SS, Horak P, Uhrig S, Buchloh J, Aybey B, Stenzinger A, Glimm H, Fröhling S, Brors B, Imbusch CD. Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. J Transl Med. 2021 May 12;19(1):204. doi: 10.1186/s12967-021-02858-7. PubMed PMID: 33980253; PubMed Central PMCID: PMC8117561.
Mock-Ohnesorge J, Mock A, Hackert T, Fröhling S, Schenz J, Poschet G, Jäger D, Büchler MW, Uhle F, Weigand MA. Perioperative changes in the plasma metabolome of patients receiving general anesthesia for pancreatic cancer surgery. Oncotarget. 2021 May 11;12(10):996-1010. doi: 10.18632/oncotarget.27956. eCollection 2021 May 11. PubMed PMID: 34012512; PubMed Central PMCID: PMC8121611.
Scheller M, Ludwig AK, Göllner S, Rohde C, Krämer S, Stäble S, Janssen M, Müller JA, He L, Bäumer N, Arnold C, Gerß J, Schönung M, Thiede C, Niederwieser C, Niederwieser D, Serve H, Berdel WE, Thiem U, Hemmerling I, Leuschner F, Plass C, Schlesner M, Zaugg J, Milsom MD, Trumpp A, Pabst C, Lipka DB, Müller-Tidow C. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nat Cancer. 2021 May;2(5):527-544. doi: 10.1038/s43018-021-00213-9. Epub 2021 May 25. PubMed PMID: 35122024.
Höhn J, Krieghoff-Henning E, Jutzi TB, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, Schlager JG, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Hekler A, Fröhling S, Lipka DB, Kather JN, Krahl D, Ferrara G, Haggenmüller S, Brinker TJ. Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. Eur J Cancer. 2021 May;149:94-101. doi: 10.1016/j.ejca.2021.02.032. Epub 2021 Apr 7. PubMed PMID: 33838393.
Hübschmann D, Jopp-Saile L, Andresen C, Krämer S, Gu Z, Heilig CE, Kreutzfeldt S, Teleanu V, Fröhling S, Eils R, Schlesner M. Analysis of mutational signatures with yet another package for signature analysis. Genes Chromosomes Cancer. 2021 May;60(5):314-331. doi: 10.1002/gcc.22918. Epub 2020 Dec 31. PubMed PMID: 33222322.
Hanf D, Heining C, Laaber K, Nebelung H, Uhrig S, Hutter B, Jahn A, Richter D, Aust D, Herbst F, Fröhling S, Glimm H, Folprecht G. Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3^G623R Solvent-Front Mutation. JCO Precis Oncol. 2021;5. doi: 10.1200/PO.20.00278. eCollection 2021. PubMed PMID: 34250401; PubMed Central PMCID: PMC8232550.
Hlevnjak M, Schulze M, Elgaafary S, Fremd C, Michel L, Beck K, Pfütze K, Richter D, Wolf S, Horak P, Kreutzfeldt S, Pixberg C, Hutter B, Ishaque N, Hirsch S, Gieldon L, Stenzinger A, Springfeld C, Smetanay K, Seitz J, Mavratzas A, Brors B, Kirsten R, Schuetz F, Fröhling S, Sinn HP, Jäger D, Thewes V, Zapatka M, Lichter P, Schneeweiss A. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precis Oncol. 2021;5. doi: 10.1200/PO.20.00248. eCollection 2021. PubMed PMID: 34036222; PubMed Central PMCID: PMC8140780.
Volckmar AL, Christopoulos P, Kirchner M, Allgäuer M, Neumann O, Budczies J, Rempel E, Horak P, Glade J, Goldschmid H, Seker-Cin H, Brandt R, Kriegsmann M, Leichsenring J, Winter H, Faehling M, Fischer JR, Heußel CP, Herth F, Brummer T, Fröhling S, Schirmacher P, Thomas M, Endris V, Penzel R, Kazdal D, Bochtler T, Stenzinger A. Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field. Lung Cancer. 2021 Apr;154:131-141. doi: 10.1016/j.lungcan.2021.02.022. Epub 2021 Feb 19. PubMed PMID: 33667718.
Mayakonda A, Schönung M, Hey J, Batra RN, Feuerstein-Akgoz C, Köhler K, Lipka DB, Sotillo R, Plass C, Lutsik P, Toth R. Methrix: an R/Bioconductor package for systematic aggregation and analysis of bisulfite sequencing data. Bioinformatics. 2021 Apr 1;36(22-23):5524-5525. doi:10.1093/bioinformatics/btaa1048. PubMed PMID: 33346800.
Lenschow C, Fuss CT, Kircher S, Buck A, Kickuth R, Reibetanz J, Wiegering A, Stenzinger A, Hübschmann D, Germer CT, Fassnacht M, Fröhling S, Schlegel N, Kroiss M. Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Front Endocrinol (Lausanne). 2021;12:643328. doi: 10.3389/fendo.2021.643328. eCollection 2021. PubMed PMID: 33833736; PubMed Central PMCID: PMC8021949.
Bekos C, Pils D, Dekan S, Hofstetter G, Horak P, Reinthaller A, Polterauer S, Schwameis R, Aust S. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. Sci Rep. 2021 Mar 18;11(1):6400. doi: 10.1038/s41598-021-85966-0. PMID: 33737722; PMCID: PMC7973418.
Wahjudi LW, Bernhardt S, Abnaof K, Horak P, Kreutzfeldt S, Heining C, Borgoni S, Becki C, Berg D, Richter D, Hutter B, Uhrig S, Pfütze K, Leichsenring J, Glimm H, Brors B, von Kalle C, Stenzinger A, Korf U, Fröhling S, Wiemann S. Integrating proteomics into precision oncology. Int J Cancer. 2021 Mar 15;148(6):1438-1451. doi: 10.1002/ijc.33301. Epub 2020 Sep 25. PubMed PMID: 32949162.
Uhrig S, Ellermann J, Walther T, Burkhardt P, Fröhlich M, Hutter B, Toprak UH, Neumann O, Stenzinger A, Scholl C, Fröhling S, Brors B. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021 Mar;31(3):448-460. doi: 10.1101/gr.257246.119. Epub 2021 Jan 13. PubMed PMID: 33441414; PubMed Central PMCID: PMC7919457.
Maron RC, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hauschild A, French LE, Schlaak M, Ghoreschi K, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Hekler A, Krieghoff-Henning E, Kather JN, Fröhling S, Lipka DB, Brinker TJ. Robustness of convolutional neural networks in recognition of pigmented skin lesions. Eur J Cancer. 2021 Mar;145:81-91. doi: 10.1016/j.ejca.2020.11.020. Epub 2021 Jan 7. PubMed PMID: 33423009.
Seidensaal K, Kieser M, Hommertgen A, Jaekel C, Harrabi SB, Herfarth K, Mechtesheimer G, Lehner B, Schneider M, Nienhueser H, Fröhling S, Egerer G, Debus J, Uhl M. Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial. Trials. 2021 Feb 12;22(1):134. doi: 10.1186/s13063-021-05069-z. PubMed PMID: 33579340; PubMed Central PMCID: PMC7881463.
Schmitt M, Maron RC, Hekler A, Stenzinger A, Hauschild A, Weichenthal M, Tiemann M, Krahl D, Kutzner H, Utikal JS, Haferkamp S, Kather JN, Klauschen F, Krieghoff-Henning E, Fröhling S, von Kalle C, Brinker TJ. Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. J Med Internet Res. 2021 Feb 2;23(2):e23436. doi: 10.2196/23436. PubMed PMID: 33528370; PubMed Central PMCID: PMC7886613.
Niemöller C, Wehrle J, Riba J, Claus R, Renz N, Rhein J, Bleul S, Stosch JM, Duyster J, Plass C, Lutsik P, Lipka DB, Lübbert M, Becker H. Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction. Commun Biol. 2021 Feb 1;4(1):153. doi: 10.1038/s42003-021-01661-w. PubMed PMID: 33526904; PubMed Central PMCID: PMC7851132.
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, Blattner M, Worst B, Heilig CE, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, Selt F, Ecker J, Sturm D, Pajtler KW, Reinhardt A, Wefers AK, Sievers P, Ebrahimi A, Suwala A, Fernández-Klett F, Casalini B, Korshunov A, Hovestadt V, Kommoss FKF, Kriegsmann M, Schick M, Bewerunge-Hudler M, Milde T, Witt O, Kulozik AE, Kool M, Romero-Pérez L, Grünewald TGP, Kirchner T, Wick W, Platten M, Unterberg A, Uhl M, Abdollahi A, Debus J, Lehner B, Thomas C, Hasselblatt M, Paulus W, Hartmann C, Staszewski O, Prinz M, Hench J, Frank S, Versleijen-Jonkers YMH, Weidema ME, Mentzel T, Griewank K, de Álava E, Martín JD, Gastearena MAI, Chang KT, Low SYY, Cuevas-Bourdier A, Mittelbronn M, Mynarek M, Rutkowski S, Schüller U, Mautner VF, Schittenhelm J, Serrano J, Snuderl M, Büttner R, Klingebiel T, Buslei R, Gessler M, Wesseling P, Dinjens WNM, Brandner S, Jaunmuktane Z, Lyskjær I, Schirmacher P, Stenzinger A, Brors B, Glimm H, Heining C, Tirado OM, Sáinz-Jaspeado M, Mora J, Alonso J, Del Muro XG, Moran S, Esteller M, Benhamida JK, Ladanyi M, Wardelmann E, Antonescu C, Flanagan A, Dirksen U, Hohenberger P, Baumhoer D, Hartmann W, Vokuhl C, Flucke U, Petersen I, Mechtersheimer G, Capper D, Jones DTW, Fröhling S, Pfister SM, von Deimling A. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021 Jan 21;12(1):498. doi: 10.1038/s41467-020-20603-4. PubMed PMID: 33479225; PubMed Central PMCID: PMC7819999.
Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Fröhling S, Peters S, Seliger B, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. Oncoimmunology. 2021 Jan 11;10(1):1860586. doi: 10.1080/2162402X.2020.1860586. PubMed PMID: 33520406; PubMed Central PMCID: PMC7808386.
Schönung M, Meyer J, Nöllke P, Olshen AB, Hartmann M, Murakami N, Wakamatsu M, Okuno Y, Plass C, Loh ML, Niemeyer CM, Muramatsu H, Flotho C, Stieglitz E, Lipka DB. International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. Clin Cancer Res. 2021 Jan 1;27(1):158-168. doi: 10.1158/1078-0432.CCR-20-3184. Epub 2020 Nov 2. PubMed PMID: 33139265; PubMed Central PMCID: PMC7785676.

Loosen SH, Gaisa NT, Schmeding M, Heining C, Uhrig S, Wirtz TH, Kalverkamp S, Spillner J, Tacke F, Stenzinger A, Glimm H, Fröhling S, Trautwein C, Roderburg C, Longerich T, Neumann UP, Luedde T. Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma. Case Rep Gastroenterol. 2020 Sep-Dec;14(3):658-667. doi: 10.1159/000511034. eCollection 2020 Sep-Dec. PubMed PMID: 33442346; PubMed Central PMCID: PMC7772835.
Mc Connell L, Gazdova J, Beck K, Srivastava S, Harewood L, Stewart JP, Hübschmann D, Stenzinger A, Glimm H, Heilig CE, Fröhling S, Gonzalez D. Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. Cancers (Basel). 2020 Dec 3;12(12). doi: 10.3390/cancers12123627. PubMed PMID: 33287361; PubMed Central PMCID: PMC7761870.
Słabicki M, Yoon H, Koeppel J, Nitsch L, Roy Burman SS, Di Genua C, Donovan KA, Sperling AS, Hunkeler M, Tsai JM, Sharma R, Guirguis A, Zou C, Chudasama P, Gasser JA, Miller PG, Scholl C, Fröhling S, Nowak RP, Fischer ES, Ebert BL. Small-molecule-induced polymerization triggers degradation of BCL6. Nature. 2020 Dec;588(7836):164-168. doi: 10.1038/s41586-020-2925-1. Epub 2020 Nov 18. PubMed PMID: 33208943; PubMed Central PMCID: PMC7816212.
Jensen P, Carlet M, Schlenk RF, Weber A, Kress J, Brunner I, Słabicki M, Grill G, Weisemann S, Cheng YY, Jeremias I, Scholl C, Fröhling S. Requirement for LIM kinases in acute myeloid leukemia. Leukemia. 2020 Dec;34(12):3173-3185. doi: 10.1038/s41375-020-0943-5. Epub 2020 Jun 26. PubMed PMID: 32591645; PubMed Central PMCID: PMC7612252.
Ihrig A, Richter J, Grüllich C, Apostolidis L, Horak P, Villalobos M, Grapp M, Friederich HC, Maatouk I. Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. J Cancer Res Clin Oncol. 2020 Dec;146(12):3189-3198. doi: 10.1007/s00432-020-03336-1. Epub 2020 Aug 19. PMID: 32813113; PMCID: PMC7679331.
Kutzner H, Jutzi TB, Krahl D, Krieghoff-Henning EI, Heppt MV, Hekler A, Schmitt M, Maron RCR, Fröhling S, von Kalle C, Brinker TJ. Überdiagnose von Melanomen - Ursachen, Konsequenzen und Lösungsansätze. J Dtsch Dermatol Ges. 2020 Nov;18(11):1236-1244. doi: 10.1111/ddg.14233_g. Review. PubMed PMID: 33251725.
Lehmann LH, Fröhling S. [Mechanisms of cardiotoxicity of oncological therapies]. Internist (Berl). 2020 Nov;61(11):1132-1139. doi: 10.1007/s00108-020-00881-2. Review. PubMed PMID: 33034675.
Kutzner H, Jutzi TB, Krahl D, Krieghoff-Henning EI, Heppt MV, Hekler A, Schmitt M, Maron RCR, Fröhling S, von Kalle C, Brinker TJ. Overdiagnosis of melanoma - causes, consequences and solutions. J Dtsch Dermatol Ges. 2020 Nov;18(11):1236-1243. doi: 10.1111/ddg.14233. Epub 2020 Aug 25. Review. PubMed PMID: 32841508.
Sill M, Plass C, Pfister SM, Lipka DB. Molecular tumor classification using DNA methylome analysis. Hum Mol Genet. 2020 Oct 20;29(R2):R205-R213. doi: 10.1093/hmg/ddaa147. Review. PubMed PMID: 32657331.
Scherr AL, Mock A, Gdynia G, Schmitt N, Heilig CE, Korell F, Rhadakrishnan P, Hoffmeister P, Metzeler KH, Schulze-Osthoff K, Illert AL, Boerries M, Trojan J, Waidmann O, Falkenhorst J, Siveke J, Jost PJ, Bitzer M, Malek NP, Vecchione L, Jelas I, Brors B, Glimm H, Stenzinger A, Grekova SP, Gehrig T, Schulze-Bergkamen H, Jäger D, Schirmacher P, Heikenwalder M, Goeppert B, Schneider M, Fröhling S, Köhler BC. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Cell Death Dis. 2020 Oct 17;11(10):875. doi: 10.1038/s41419-020-03092-7. PubMed PMID: 33070156; PubMed Central PMCID: PMC7568722.
Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, Treue D, Stenzinger A, Glimm H, Fröhling S, Kindler T, Brandts CH, Schulze-Osthoff K, Weichert W, Tinhofer I, Klauschen F, Keilholz U, Beule D, Rieke DT. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. Int J Cancer. 2020 Oct 15;147(8):2293-2302. doi: 10.1002/ijc.33123. Epub 2020 Jun 18. PubMed PMID: 32468570.
Heilig CE, Badoglio M, Labopin M, Fröhling S, Secondino S, Heinz J, Nicolas-Virelizier E, Blaise D, Korenbaum C, Santoro A, Verbeek M, Krüger W, Siena S, Passweg JR, Di Nicola M, Rifón J, Dreger P, Koehl U, Chabannon C, Pedrazzoli P. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. ESMO Open. 2020 Oct;5(5):e000860. doi: 10.1136/esmoopen-2020-000860. PubMed PMID: 33097652; PubMed Central PMCID: PMC7590345.
Heilig CE, Horak P, Lipka DB, Mock A, Uhrig S, Kreutzfeldt S, Richter S, Gieldon L, Fröhlich M, Hutter B, Hübschmann D, Teleanu V, Schmier JW, Philipzen J, Beuthien-Baumann B, Schröck E, von Deimling A, Bauer S, Heining C, Mechtersheimer G, Stenzinger A, Brors B, Wardelmann E, Glimm H, Hartmann W, Fröhling S. Germline SDHB-inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes Cancer. 2020 Oct;59(10):601-608. doi: 10.1002/gcc.22876. Epub 2020 Jun 26. PubMed PMID: 32501622.
Horak P, Uhrig S, Witzel M, Gil-Farina I, Hutter B, Rath T, Gieldon L, Balasubramanian GP, Pastor X, Heilig CE, Richter D, Schröck E, Ball CR, Brors B, Braun CJ, Albert MH, Scholl C, von Kalle C, Schmidt M, Fröhling S, Klein C, Glimm H. Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia. 2020 Oct;34(10):2785-2789. doi: 10.1038/s41375-020-0779-z. Epub 2020 Mar 3. PubMed PMID: 32127638; PubMed Central PMCID: PMC8321895.
Maron RC, Utikal JS, Hekler A, Hauschild A, Sattler E, Sondermann W, Haferkamp S, Schilling B, Heppt MV, Jansen P, Reinholz M, Franklin C, Schmitt L, Hartmann D, Krieghoff-Henning E, Schmitt M, Weichenthal M, von Kalle C, Fröhling S, Brinker TJ. Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study. J Med Internet Res. 2020 Sep 11;22(9):e18091. doi: 10.2196/18091. PubMed PMID: 32915161; PubMed Central PMCID: PMC7519424.
Munkhbaatar E, Dietzen M, Agrawal D, Anton M, Jesinghaus M, Boxberg M, Pfarr N, Bidola P, Uhrig S, Höckendorf U, Meinhardt AL, Wahida A, Heid I, Braren R, Mishra R, Warth A, Muley T, Poh PSP, Wang X, Fröhling S, Steiger K, Slotta-Huspenina J, van Griensven M, Pfeiffer F, Lange S, Rad R, Spella M, Stathopoulos GT, Ruland J, Bassermann F, Weichert W, Strasser A, Branca C, Heikenwalder M, Swanton C, McGranahan N, Jost PJ. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat Commun. 2020 Sep 10;11(1):4527. doi: 10.1038/s41467-020-18372-1. PubMed PMID: 32913197; PubMed Central PMCID: PMC7484793.
Rippinger N, Fischer C, Haun MW, Rhiem K, Grill S, Kiechle M, Cremer FW, Kast K, Nguyen HP, Ditsch N, Kratz CP, Vogel J, Speiser D, Hettmer S, Glimm H, Fröhling S, Jäger D, Seitz S, Hahne A, Maatouk I, Sutter C, Schmutzler RK, Dikow N, Schott S. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer. 2020 Sep 1;126(17):4032-4041. doi: 10.1002/cncr.33004. Epub 2020 Jun 18. PubMed PMID: 32557628.
Słabicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, Donovan KA, Sievers QL, Koeppel J, Suchyta D, Sperling AS, Fink EC, Gasser JA, Wang LR, Corsello SM, Sellar RS, Jan M, Gillingham D, Scholl C, Fröhling S, Golub TR, Fischer ES, Thomä NH, Ebert BL. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 Sep;585(7824):293-297. doi: 10.1038/s41586-020-2374-x. Epub 2020 Jun 3. PubMed PMID: 32494016; PubMed Central PMCID: PMC7486275.
Busch E, Kreutzfeldt S, Agaimy A, Mechtersheimer G, Horak P, Brors B, Hutter B, Fröhlich M, Uhrig S, Mayer P, Schröck E, Stenzinger A, Glimm H, Jäger D, Springfeld C, Fröhling S, Zschäbitz S. Successful BRAF/MEK inhibition in a patient with BRAF^V600E-mutated extrapancreatic acinar cell carcinoma. Cold Spring Harb Mol Case Stud. 2020 Aug;6(4). doi: 10.1101/mcs.a005553. Print 2020 Aug. PubMed PMID: 32843432; PubMed Central PMCID: PMC7476408.
de Rojas T, Kasper B, Van der Graaf W, Pfister SM, Bielle F, Ribalta T, Shenjere P, Preusser M, Fröhling S, Golfinopoulos V, Morfouace M, McCabe MG. EORTC SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. Int J Cancer. 2020 Aug 15;147(4):1180-1184. doi: 10.1002/ijc.32651. Epub 2019 Sep 14. PubMed PMID: 31465545; PubMed Central PMCID: PMC7383917.
Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer. 2020 Aug;135:1-7. doi: 10.1016/j.ejca.2020.04.019. Epub 2020 Jun 7. Review. PubMed PMID: 32521293.
Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020 Jul;26(7):992-994. doi: 10.1038/s41591-020-0969-2. PubMed PMID: 32632195.
Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, Stolarczyk M, Mallm JP, Herbst SA, Bruch PM, Balke-Want H, Hundemer M, Rippe K, Goeppert B, Seiffert M, Brors B, Mechtersheimer G, Zenz T, Peifer M, Chapuy B, Schlesner M, Müller-Tidow C, Fröhling S, Huber W, Anders S, Dietrich S. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nat Cell Biol. 2020 Jul;22(7):896-906. doi: 10.1038/s41556-020-0532-x. Epub 2020 Jun 15. PubMed PMID: 32541878.
van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Author Correction: Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 Jul;26(7):1146. doi: 10.1038/s41591-020-0948-7. PubMed PMID: 32494062; PubMed Central PMCID: PMC7269160.
Kommoss FK, Chang KT, Stichel D, Banito A, Jones DT, Heilig CE, Fröhling S, Sahm F, Stenzinger A, Hartmann W, Mechtersheimer G, Sinn HP, Schmidt D, Kommoss F, von Deimling A, Koelsche C. Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications. J Pathol Clin Res. 2020 Jul;6(3):178-184. doi: 10.1002/cjp2.165. Epub 2020 Apr 30. PubMed PMID: 32352245; PubMed Central PMCID: PMC7339170.
Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, Pfarr N, Siebolts U, Hummel M, Herold S, Andreas J, Zoche M, Tögel L, Rempel E, Maas J, Merino D, Stewart M, Zaoui K, Schlesner M, Glimm H, Fröhling S, Allen J, Horst D, Baretton G, Wickenhauser C, Tiemann M, Evert M, Moch H, Kirchner T, Büttner R, Schirmacher P, Jung A, Haller F, Weichert W, Dietel M. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. J Thorac Oncol. 2020 Jul;15(7):1177-1189. doi: 10.1016/j.jtho.2020.01.023. Epub 2020 Feb 29. PubMed PMID: 32119917.
Vu T, Straube J, Porter AH, Bywater M, Song A, Ling V, Cooper L, Pali G, Bruedigam C, Jacquelin S, Green J, Magor G, Perkins A, Chalk AM, Walkley CR, Heidel FH, Mukhopadhyay P, Cloonan N, Gröschel S, Mallm JP, Fröhling S, Scholl C, Lane SW. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nat Commun. 2020 Jun 15;11(1):3021. doi: 10.1038/s41467-020-16840-2. PubMed PMID: 32541670; PubMed Central PMCID: PMC7296000.
Seidensaal K, Harrabi SB, Weykamp F, Herfarth K, Welzel T, Mechtersheimer G, Lehner B, Schneider M, Fröhling S, Egerer G, Debus J, Uhl M. Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution. Radiat Oncol. 2020 Jun 5;15(1):143. doi: 10.1186/s13014-020-01565-9. PubMed PMID: 32503580; PubMed Central PMCID: PMC7275436.
Jutzi TB, Krieghoff-Henning EI, Holland-Letz T, Utikal JS, Hauschild A, Schadendorf D, Sondermann W, Fröhling S, Hekler A, Schmitt M, Maron RC, Brinker TJ. Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective. Front Med (Lausanne). 2020;7:233. doi: 10.3389/fmed.2020.00233. eCollection 2020. PubMed PMID: 32671078; PubMed Central PMCID: PMC7326111.
Voronina N, Wong JKL, Hübschmann D, Hlevnjak M, Uhrig S, Heilig CE, Horak P, Kreutzfeldt S, Mock A, Stenzinger A, Hutter B, Fröhlich M, Brors B, Jahn A, Klink B, Gieldon L, Sieverling L, Feuerbach L, Chudasama P, Beck K, Kroiss M, Heining C, Möhrmann L, Fischer A, Schröck E, Glimm H, Zapatka M, Lichter P, Fröhling S, Ernst A. The landscape of chromothripsis across adult cancer types. Nat Commun. 2020 May 8;11(1):2320. doi: 10.1038/s41467-020-16134-7. PubMed PMID: 32385320; PubMed Central PMCID: PMC7210959.
Hekler A, Kather JN, Krieghoff-Henning E, Utikal JS, Meier F, Gellrich FF, Upmeier Zu Belzen J, French L, Schlager JG, Ghoreschi K, Wilhelm T, Kutzner H, Berking C, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Izar B, Maron R, Schmitt M, Fröhling S, Lipka DB, Brinker TJ. Effects of Label Noise on Deep Learning-Based Skin Cancer Classification. Front Med (Lausanne). 2020 May 6;7:177. doi: 10.3389/fmed.2020.00177. eCollection 2020. PubMed PMID: 32435646; PubMed Central PMCID: PMC7218064.
van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 May;26(5):665-671. doi: 10.1038/s41591-020-0874-8. Epub 2020 Apr 16. Review. PubMed PMID: 32405058.
Ronellenfitsch MW, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, Schittenhelm J, Schuhmann MU, Tatagiba M, Marquardt G, Wagner M, Endris V, Brandts CH, Mautner VF, Schröck E, Weichert W, Brors B, von Deimling A, Mittelbronn M, Steinbach JP, Reuss DE, Glimm H, Stenzinger A, Fröhling S. Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. J Clin Invest. 2020 May 1;130(5):2488-2495. doi: 10.1172/JCI130787. PubMed PMID: 32017710; PubMed Central PMCID: PMC7190903.
Hekler A, Utikal JS, Solass W, Schmitt M, Klode J, Schadendorf D, Sondermann W, Franklin C, Bestvater F, Krahl D, von Kalle C, Fröhling S, Brinker TJ. Reply to the letter to the editor: 'Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images'. Eur J Cancer. 2020 May;130:262-264. doi: 10.1016/j.ejca.2019.12.024. Epub 2020 Jan 30. PubMed PMID: 32008919.
Willis F, Schimmack S, Uhl M, Haefner MF, Mechtersheimer G, Hinz U, Schmidt T, Debus J, Fröhling S, Schneider M. Significance of intraoperative radiation therapy and high cumulative radiation doses in retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2020 May;46(5):905-913. doi: 10.1016/j.ejso.2019.12.014. Epub 2019 Dec 17. PubMed PMID: 31892479.
Berger AK, Mughal SS, Allgäuer M, Springfeld C, Hackert T, Weber TF, Naumann P, Hutter B, Horak P, Jahn A, Schröck E, Haag GM, Apostolidis L, Jäger D, Stenzinger A, Fröhling S, Glimm H, Heining C. Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. Pancreatology. 2020 Apr;20(3):425-432. doi: 10.1016/j.pan.2020.02.017. Epub 2020 Feb 29. PubMed PMID: 32156527.
Budczies J, Kazdal D, Allgäuer M, Christopoulos P, Rempel E, Pfarr N, Weichert W, Fröhling S, Thomas M, Peters S, Endris V, Schirmacher P, Stenzinger A. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer. 2020 Apr;142:114-119. doi: 10.1016/j.lungcan.2020.01.019. Epub 2020 Feb 1. PubMed PMID: 32143116.
Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, Schreiber AW, Feng J, Phillips K, Wang PPS, Ha T, Homan CC, King-Smith SL, Rawlings L, Vakulin C, Dubowsky A, Burdett J, Moore S, McKavanagh G, Henry D, Wells A, Mercorella B, Nicola M, Suttle J, Wilkins E, Li XC, Michaud J, Brautigan P, Cannon P, Altree M, Jaensch L, Fine M, Butcher C, D'Andrea RJ, Lewis ID, Hiwase DK, Papaemmanuil E, Horwitz MS, Natsoulis G, Rienhoff HY, Patton N, Mapp S, Susman R, Morgan S, Cooney J, Currie M, Popat U, Bochtler T, Izraeli S, Bradstock K, Godley LA, Krämer A, Fröhling S, Wei AH, Forsyth C, Mar Fan H, Poplawski NK, Hahn CN, Scott HS. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020 Mar 24;4(6):1131-1144. doi: 10.1182/bloodadvances.2019000901. PubMed PMID: 32208489; PubMed Central PMCID: PMC7094007.
Wierzbinska JA, Toth R, Ishaque N, Rippe K, Mallm JP, Klett LC, Mertens D, Zenz T, Hielscher T, Seifert M, Küppers R, Assenov Y, Lutsik P, Stilgenbauer S, Roessner PM, Seiffert M, Byrd J, Oakes CC, Plass C, Lipka DB. Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. Genome Med. 2020 Mar 18;12(1):29. doi: 10.1186/s13073-020-00724-7. PubMed PMID: 32188505; PubMed Central PMCID: PMC7081711.
Zielonka M, Debatin D, Rütten A, Fröhling S, Deimling A, Warth A, Toberer F, Enk AH, Hassel JC. Zerebral metastasiertes Dermatofibrosarcoma protuberans. J Dtsch Dermatol Ges. 2020 Feb;18(2):143-146. doi: 10.1111/ddg.13992_g. PubMed PMID: 32026638.
Zielonka M, Debatin D, Rütten A, Fröhling S, Deimling A, Warth A, Toberer F, Enk AH, Hassel JC. Cerebral metastases of a dermatofibrosarcoma protuberans. J Dtsch Dermatol Ges. 2020 Feb;18(2):143-145. doi: 10.1111/ddg.13992. Epub 2019 Dec 17. PubMed PMID: 31846212.
Mogler C, Koschny R, Heilig CE, Frohling S, Schirmacher P, Weichert W, Pfarr N. Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control. Genes Chromosomes Cancer. 2020 Feb;59(2):106-110. doi: 10.1002/gcc.22795. Epub 2019 Sep 3. PubMed PMID: 31390105.
Weinberg F, Griffin R, Fröhlich M, Heining C, Braun S, Spohr C, Iconomou M, Hollek V, Röring M, Horak P, Kreutzfeldt S, Warsow G, Hutter B, Uhrig S, Neumann O, Reuss D, Heiland DH, von Kalle C, Weichert W, Stenzinger A, Brors B, Glimm H, Fröhling S, Brummer T. Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene. 2020 Jan;39(4):814-832. doi: 10.1038/s41388-019-1021-1. Epub 2019 Sep 26. PubMed PMID: 31558800.

Aghamaliyev U, Gaitantzi H, Thomas M, Simon-Keller K, Gaiser T, Marx A, Yagublu V, Araos J, Cai C, Valous NA, Halama N, KieSondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, French LE, Berking C, Schilling B, Haferkamp S, Fröhling S, von Kalle C, Brinker TJ. Corrigendum to 'Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data' [Eur J Cancer, 119 (September 2019) Pages 30-34]. Eur J Cancer. 2019 Dec;123:171. doi: 10.1016/j.ejca.2019.10.003. Epub 2019 Nov 7. PubMed PMID: 31708276.
Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S, Stenzinger A. Variant classification in precision oncology. Int J Cancer. 2019 Dec 1;145(11):2996-3010. doi: 10.1002/ijc.32358. Epub 2019 May 21. PubMed PMID: 31008532.
Mock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schröck E, Brors B, Stenzinger A, Jäger D, Schlenk R, Glimm H, Fröhling S, Horak P. Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open. 2019;4(6):e000583. doi: 10.1136/esmoopen-2019-000583. eCollection 2019. PubMed PMID: 31798980; PubMed Central PMCID: PMC6863673.
Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. J Thorac Oncol. 2019 Nov;14(11):1935-1947. doi: 10.1016/j.jtho.2019.07.006. Epub 2019 Jul 23. PubMed PMID: 31349062.
Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. Mol Cancer Ther. 2019 Nov;18(11):1985-1996. doi: 10.1158/1535-7163.MCT-18-1224. Epub 2019 Jul 15. PubMed PMID: 31308077.
Hekler A, Utikal JS, Enk AH, Hauschild A, Weichenthal M, Maron RC, Berking C, Haferkamp S, Klode J, Schadendorf D, Schilling B, Holland-Letz T, Izar B, von Kalle C, Fröhling S, Brinker TJ. Superior skin cancer classification by the combination of human and artificial intelligence. Eur J Cancer. 2019 Oct;120:114-121. doi: 10.1016/j.ejca.2019.07.019. Epub 2019 Sep 10. PubMed PMID: 31518967.
Maron RC, Weichenthal M, Utikal JS, Hekler A, Berking C, Hauschild A, Enk AH, Haferkamp S, Klode J, Schadendorf D, Jansen P, Holland-Letz T, Schilling B, von Kalle C, Fröhling S, Gaiser MR, Hartmann D, Gesierich A, Kähler KC, Wehkamp U, Karoglan A, Bär C, Brinker TJ. Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. Eur J Cancer. 2019 Sep;119:57-65. doi: 10.1016/j.ejca.2019.06.013. Epub 2019 Aug 14. PubMed PMID: 31419752.
Sondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, French LE, Berking C, Schilling B, Haferkamp S, Fröhling S, von Kalle C, Brinker TJ. Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. Eur J Cancer. 2019 Sep;119:30-34. doi: 10.1016/j.ejca.2019.07.009. Epub 2019 Aug 8. PubMed PMID: 31401471.
Brinker TJ, Hekler A, Enk AH, Berking C, Haferkamp S, Hauschild A, Weichenthal M, Klode J, Schadendorf D, Holland-Letz T, von Kalle C, Fröhling S, Schilling B, Utikal JS. Deep neural networks are superior to dermatologists in melanoma image classification. Eur J Cancer. 2019 Sep;119:11-17. doi: 10.1016/j.ejca.2019.05.023. Epub 2019 Aug 8. PubMed PMID: 31401469.
Hekler A, Utikal JS, Enk AH, Solass W, Schmitt M, Klode J, Schadendorf D, Sondermann W, Franklin C, Bestvater F, Flaig MJ, Krahl D, von Kalle C, Fröhling S, Brinker TJ. Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images. Eur J Cancer. 2019 Sep;118:91-96. doi: 10.1016/j.ejca.2019.06.012. Epub 2019 Jul 18. PubMed PMID: 31325876.
Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A. Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol. 2019 Sep 1;30(9):1496-1506. doi: 10.1093/annonc/mdz205. PubMed PMID: 31268125.
Glocker K, Ahlbrandt J, Knurr A, Horak P, Heining C, Ückert F. Finding Options Beyond Standard of Care in Oncology: A Proposal for Workflows Utilizing Knowledge Databases. Stud Health Technol Inform. 2019 Aug 21;264:950-953. doi: 10.3233/SHTI190364. PMID: 31438064.
Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Int J Cancer. 2019 Aug 1;145(3):649-661. doi: 10.1002/ijc.32133. Epub 2019 Feb 19. PubMed PMID: 30653256.
Hekler A, Utikal JS, Enk AH, Berking C, Klode J, Schadendorf D, Jansen P, Franklin C, Holland-Letz T, Krahl D, von Kalle C, Fröhling S, Brinker TJ. Pathologist-level classification of histopathological melanoma images with deep neural networks. Eur J Cancer. 2019 Jul;115:79-83. doi: 10.1016/j.ejca.2019.04.021. Epub 2019 May 23. PubMed PMID: 31129383.
Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut. 2019 Jul;68(7):1287-1296. doi: 10.1136/gutjnl-2018-317632. Epub 2019 Feb 2. PubMed PMID: 30901310.
Feuerbach L, Sieverling L, Deeg KI, Ginsbach P, Hutter B, Buchhalter I, Northcott PA, Mughal SS, Chudasama P, Glimm H, Scholl C, Lichter P, Fröhling S, Pfister SM, Jones DTW, Rippe K, Brors B. TelomereHunter - in silico estimation of telomere content and composition from cancer genomes. BMC Bioinformatics. 2019 May 28;20(1):272. doi: 10.1186/s12859-019-2851-0. PubMed PMID: 31138115; PubMed Central PMCID: PMC6540518.
Leichsenring J, Kazdal D, Ploeger C, Allgäuer M, Endris V, Volckmar AL, Neumann O, Kirchner M, Penzel R, Rempel E, Budczies J, Schirmacher P, Fröhling S, Stenzinger A. [From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?]. Pathologe. 2019 May;40(3):235-242. doi: 10.1007/s00292-019-0608-1. PubMed PMID: 31089797.
Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S. Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201809889. PubMed PMID: 30898787; PubMed Central PMCID: PMC6505681.
Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer. 2019 May 1;144(9):2303-2312. doi: 10.1002/ijc.32002. Epub 2019 Feb 4. PubMed PMID: 30446996.
Brinker TJ, Buslaff F, Suhre JL, Silchmüller MP, Divizieva E, Wilhelm J, Hillebrand G, Penka D, Gaim B, Swoboda S, Baumermann S, Walther JW, Brieske CM, Jakob L, Baumert HM, Anhuef O, Schmidt SM, Alfitian J, Batra A, Taha L, Mons U, Hofmann FJ, Haney AC, Haney CM, Schaible S, Tran TA, Beißwenger H, Stark T, Groneberg DA, Seeger W, Srivastava A, Gall H, Holzapfel J, Rigotti NA, Baudson TG, Enk AH, Fröhling S, von Kalle C, Bernardes-Souza B, Pereira RMOS, Thomas R. Process Evaluation of a Medical Student-Delivered Smoking Prevention Program for Secondary Schools: Protocol for the Education Against Tobacco Cluster Randomized Trial. JMIR Res Protoc. 2019 Apr 11;8(4):e13508. doi: 10.2196/13508. PubMed PMID: 30973348; PubMed Central PMCID: PMC6482400.
Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9. PubMed PMID: 30967556; PubMed Central PMCID: PMC6456501.
Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C. A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8. PubMed PMID: 30852421.
Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T. Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Cold Spring Harb Mol Case Stud. 2019 Apr;5(2). doi: 10.1101/mcs.a003657. Print 2019 Apr. PubMed PMID: 30833416; PubMed Central PMCID: PMC6549578.
Scholl C, Fröhling S. Exploiting rare driver mutations for precision cancer medicine. Curr Opin Genet Dev. 2019 Feb;54:1-6. doi: 10.1016/j.gde.2019.02.004. Epub 2019 Mar 4. Review. PubMed PMID: 30844512.
Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, Kirchner M, Leichsenring J, Lier A, von Winterfeld M, Penzel R, Christopoulos P, Thomas M, Fröhling S, Schirmacher P, Budczies J, Stenzinger A. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. Int J Cancer. 2019 Feb 15;144(4):848-858. doi: 10.1002/ijc.31878. Epub 2018 Dec 4. PubMed PMID: 30238975.
Tapia-Laliena MÁ, Korzeniewski N, Peña-Llopis S, Scholl C, Fröhling S, Hohenfellner M, Duensing A, Duensing S. Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability. Oncogenesis. 2019 Jan 9;8(1):4. doi: 10.1038/s41389-018-0110-2. PubMed PMID: 30631037; PubMed Central PMCID: PMC6328621.sslich T, Ebert M, Grützmann R, Rückert F, Breitkopf-Heinlein K. Downregulation of SPARC Is Associated with Epithelial-Mesenchymal Transition and Low Differentiation State of Biliary Tract Cancer Cells. Eur Surg Res. 2019;60(1-2):1-12. doi: 10.1159/000494734. Epub 2019 Jan 16.
Akbaba S, Ahmed D, Mock A, Held T, Bahadir S, Lang K, Syed M, Hoerner-Rieber J, Forster T, Federspil P, Herfarth K, Plinkert P, Debus J, Adeberg S. Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience.
Akbaba S, Heusel A, Mock A, Held T, Lang K, Hoerner-Rieber J, Forster T, Katayama S, Kargus S, Rieken S, Plinkert P, Herfarth K, Debus J, Adeberg S. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience. Oral Oncol. 2019 Oct;97:115-123. doi: 10.1016/j.oraloncology.2019.08.018. Epub 2019 Sep 5.
Akbaba S, Mock A, Hoerner-Rieber J, Held T, Katayama S, Forster T, Freudlsperger C, Rieken S, Herfarth K, Plinkert P, Debus J, Adeberg S. Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck. Front Oncol. 2019 Aug 13;9:755. doi: 10.3389/fonc.2019.00755. eCollection 2019.
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
Albrecht J, Baumann F, Wiskemann J. Erfassung der Versorgungsmerkmale von Krebsnachsorge-Sportgruppen in Nord- und Südbaden [Evaluation of cancer rehabilitation groups in North- and South Baden]. LZS (accepted June 06th, 2019)
Albrecht T, Rausch M, Roessler S, Geissler V, Albrecht M, Halske C, Seifert C, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil-Warth A, Busch E, Köhler B, Rupp C, Weiss KH, Springfeld C, Röcken C, Schirmacher P, Goeppert B. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Arch. 2019 Dec 14. doi: 10.1007/s00428-019-02706-6. [Epub ahead of print]
Albrecht T, Rausch M, Rössler S, Albrecht M, Braun JD, Geissler V, Mehrabi A, Vogel MN, Pathil-Warth A, Mechtersheimer G, Renner M, Rupp C, Weiss KH, Busch E, Köhler B, Springfeld C, Schirmacher P, Goeppert B. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. BMC Cancer. 2019 Dec 5;19(1):1191. doi: 10.1186/s12885-019-6320-y.
Ann Surg Oncol. 2019 Nov;26(12):3892-3901. doi: 10.1245/s10434-019-07635-x. Epub 2019 Jul 26.
Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Oncotarget. 2019 Jan 1;10(1):17-29. doi: 10.18632/oncotarget.26523. eCollection 2019 Jan 1.
Aprupe L, Litjens G, Brinker TJ, van der Laak J, Grabe N. Robust and accurate quantification of biomarkers of immune cells in lung cancer micro-environment using deep convolutional neural networks. PeerJ. 2019 Apr 10;7:e6335. doi: 10.7717/peerj.6335. eCollection 2019.
Arians N, Kieser M, Benner L, Rochet N, Schröder L, Katayama S, Herfarth K, Schubert K, Schneeweiss A, Sohn C, Lindel K, Debus J. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. Radiat Oncol. 2019 Oct 21;14(1):179. doi: 10.1186/s13014-019-1381-2.
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061.
Backhaus PS, Veinalde R, Hartmann L, Dunder JE, Jeworowski LM, Albert J, Hoyler B, Poth T, Jäger D, Ungerechts G, Engeland CE. Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists. Viruses. 2019 Oct 3;11(10). pii: E914. doi: 10.3390/v11100914.
Bernard P, Savard J. Steindorf K, Sweegers MG, Courneya K, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvão DA, Chinapaw MJ, Stuiver MM, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Bohus M, Thorsen L, Schmidt ME, Ulrich CM, Sonke GS, van Harten WH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, Buffart LM. Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses. J Psychosom Res. 2019 Sep;124:109746. doi: 10.1016/j.jpsychores.2019.109746. Epub 2019 Jun 23.
Campbell KL, Winters-Stone K, Wiskemann J, May A, Schwartz A, Courneya KS, Zucker D, Matthews C, Ligibel J, Gerber L, Morris S, Patel A, Hue T, Perna F, Schmitz K (2019). Exercise Guidelines for Cancer Survivors: Consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020 Mar;34(3):914-918. doi: 10.1038/s41375-019-0589-3. Epub 2019 Oct 14.
Clauss D, Quirmbach F, Wiskemann J, Rosenberger F. Adverse Events beim Training mit onkologischen Patienten: Wie sicher ist das Training außerhalb klinischer Studien? [Adverse events in exercise oncology: How safe is training outside of clinical trials?]. Bewegungstherapie und Gesundheitssport 2019, 35: 194–201
Das K, Eisel D, Vormehr M, Müller-Decker K, Hommertgen A, Jäger D, Zörnig I, Feuerer M, Kopp-Schneider A, Osen W, Eichmüller SB. A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice. BMC Cancer. 2019 Sep 13;19(1):914. doi: 10.1186/s12885-019-6102-6.
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16.
DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, Röllig C, Strickland SA, Thol F, Valera SZ, Dasgupta K, Berkowitz N, Stuart RK. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 Oct;85:106197. doi: 10.1016/j.leukres.2019.106197. Epub 2019 Aug 1.
Edelmann D, Habermehl C, Schlenk RF, Benner A. Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls. Biom J. 2020 Mar;62(2):311-329. doi: 10.1002/bimj.201800390. Epub 2019 Sep 25.
Ehrenberg KR, Gao J, Oppel F, Frank S, Kang N, Dieter SM, Herbst F, Möhrmann L, Dubash TD, Schulz ER, Strakerjahn H, Giessler KM, Weber S, Oberlack A, Rief EM, Strobel O, Bergmann F, Lasitschka F, Weitz J, Glimm H, Ball CR. Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer. Cells. 2019 Feb 10;8(2). pii: E142. doi: 10.3390/cells8020142.
Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL; NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK. Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x. Epub 2019 Feb 21.
Farzanegi P, Asadi M, Abdi A, Etemadian M, Amani, M, Amrollah V, Shahri, F, Gholami V, Abdi Z, Moradi L, Ghorbani S, Fallah Z, Wiskemann J, Azarbayjani MA. Swimming exercise in combination with garlic extract administration as a therapy against doxorubicin-induced hepatic, heart and renal toxicity to rats. https://www.tandfonline.com/doi/abs/10.1080/15569543.2018.1559194?journalCode=itxr20
Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15.
Fasching PA, Schneeweiss A, Kolberg HC, Ettl J, Fehm TN, Overkamp F, Lüftner D. Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Curr Opin Obstet Gynecol. 2019 Feb;31(1):67-75. doi: 10.1097/GCO.0000000000000510.
Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, de Miranda NFDCC, Trajanoski Z. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019 May 24;11(1):34. doi: 10.1186/s13073-019-0638-6.
Forster T, Akbaba S, Schmitt D, Krug D, El Shafie R, Oelmann-Avendano J, Lindel K, König L, Arians N, Bernhardt D, Marmé F, Schneeweiss A, Heil J, Sohn C, Debus J, Hörner-Rieber J. Second breast conserving therapy after ipsilateral breast tumor recurrence - a 10-year experience of re-irradiation. J Contemp Brachytherapy. 2019 Aug;11(4):312-319. doi: 10.5114/jcb.2019.87001. Epub 2019 Aug 29.
Forster T, Huettner FJ, Springfeld C, Loehr M, Kalkum E, Hackbusch M, Hackert T, Diener MK, Probst P. Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Oncology. 2020;98(1):53-60. doi: 10.1159/000502844. Epub 2019 Oct 2.
Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, Thewes V, Lichter P, Schirmacher P, Kloor M, Marmé F, Schütz F, Kosaloglu Z, Sinn HP, Jäger D, Schneeweiss A. Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care (Basel). 2019 Mar;14(1):53-59. doi: 10.1159/000492580. Epub 2018 Nov 14.
Fremd C, Jaeger D, Schneeweiss A. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. Expert Rev Anticancer Ther. 2019 Jan;19(1):29-42. doi: 10.1080/14737140.2019.1537785. Epub 2018 Oct 29.
Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching PA, Gerber B, Bauerfeind I, Nitz U, Lück HJ, Hanusch C, Thomssen C, Untch M, Nekljudova V, Mehta K, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer. 2019 Nov;26(6):826-834. doi: 10.1007/s12282-019-00990-3. Epub 2019 Jun 28.
Gangkofner DS, Holzinger D, Schroeder L, Eichmüller SB, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic J, Marienfeld RB, Möller P, Völkel G, Kraus JM, Kestler HA, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Doescher J, Hoffmann TK, Pawlita M, Butt J, Waterboer T, Laban S. Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. Int J Cancer. 2019 Dec 15;145(12):3436-3444. doi: 10.1002/ijc.32623. Epub 2019 Aug 26.
Goeppert B, Renner M, Singer S, Albrecht T, Zhang Q, Mehrabi A, Pathil A, Springfeld C, Köhler B, Rupp C, Weiss KH, Kühl AA, Arsenic R, Pape UF, Vogel A, Schirmacher P, Roessler S, Utku N. Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. Sci Rep. 2019 Mar 13;9(1):4338. doi: 10.1038/s41598-019-40487-9.
Goeppert B, Roessler S, Renner M, Loeffler M, Singer S, Rausch M, Albrecht T, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol. 2019 May 8;14(1):36. doi: 10.1186/s13000-019-0813-5.
Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Pfeiffenberger J, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer. 2019 Jan;120(1):109-114. doi: 10.1038/s41416-018-0199-2. Epub 2018 Oct 31.
Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23.
Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, Heger U, Apostolidis L, Berger AK, Springfeld C, Lasitschka F, Jäger D, von Knebel Doeberitz M, Kloor M. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int J Cancer. 2019 Apr 1;144(7):1697-1703. doi: 10.1002/ijc.32030. Epub 2019 Jan 4.
Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. J Bone Oncol. 2018 Oct 2;14:010-10. doi: 10.1016/j.jbo.2018.09.010. eCollection 2019 Feb.
Halama N. Machine learning for tissue diagnostics in oncology: brave new world. Br J Cancer. 2019 Sep;121(6):431-433. doi: 10.1038/s41416-019-0535-1. Epub 2019 Aug 9.
Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D. Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319. doi: 10.1055/a-1039-4458. Epub 2019 Dec 11.
Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N, Taran FA, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Overkamp F, Schneeweiss A, Tesch H. Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):256-267. doi: 10.1055/a-0842-6614. Epub 2019 Mar 12.
Haussmann A, Ungar N, Tsiouris A, Sieverding M, Wiskemann J*, Steindorf K*. The influence of cancer patient characteristics on the recommendation of physical activity by healthcare professionals. Int J Behav Med. 2020 Feb;27(1):65-78. doi: 10.1007/s12529-019-09833-z.
Heger P, Probst P, Wiskemann J, Steindorf K, Diener MK, Mihaljevic A. A Systematic Review and Meta-analysis of Physical Exercise Prehabilitation in Major Abdominal Surgery (PROSPERO 2017 CRD42017080366). J Gastrointest Surg. 2019 Jun 21. doi: 10.1007/s11605-019-04287-w. [Epub ahead of print]
Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford). HPB (Oxford). 2020 Feb;22(2):224-232. doi: 10.1016/j.hpb.2019.06.012. Epub 2019 Jul 30.
Heidbuechel JPW, Engeland CE. Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. J Vis Exp. 2019 Jan 7;(143). doi: 10.3791/58651.
Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Schneeweiss A, Heil J. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Breast Cancer Res Treat. 2019 Jan;173(2):429-438. doi: 10.1007/s10549-018-5009-2. Epub 2018 Oct 12.
Hütter-Krönke ML, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk RF. Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. Haematologica. 2019 Feb;104(2):e63-e64. doi: 0.3324/haematol.2018.199794. Epub 2018 Aug 31.
Idler I, Schickhardt C, Cornelius K, Winkler E. "» Stellungnahme zur Herausgabe genomischer Rohdaten an Patient_innen und Studienteilnehmende« Marsilius-Kolleg, Heidelberg, 2019.
Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C. Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. J Natl Cancer Inst. 2019 Jan 1;111(1):69-77. doi: 10.1093/jnci/djy076.
Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J. Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280. doi: 10.1055/a-0842-6661. Epub 2019 Mar 12.
Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Res Treat. 2019 Jan;173(1):155-165. doi: 10.1007/s10549-018-4972-y. Epub 2018 Oct 1.
Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. Recent Advances targeting CCR5 for Cancer and its Role in Immuno-Oncology. Cancer Res. 2019 Oct 1;79(19):4801-4807. doi: 10.1158/0008-5472.CAN-19-1167. Epub 2019 Jul 10. Review.
Kather JN, Halama N. Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. Br J Cancer. 2019 Apr;120(9):871-882. doi: 10.1038/s41416-019-0441-6. Epub 2019 Apr 2. Review.
Kather JN, Krisam J, Charoentong P, Luedde T, Herpel E, Weis CA, Gaiser T, Marx A, Valous NA, Ferber D, Jansen L, Reyes-Aldasoro CC, Zörnig I, Jäger D, Brenner H, Chang-Claude J, Hoffmeister M, Halama N. Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study. PLoS Med. 2019 Jan 24;16(1):e1002730. doi: 10.1371/journal.pmed.1002730. eCollection 2019 Jan.
Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, Marx A, Boor P, Tacke F, Neumann UP, Grabsch HI, Yoshikawa T, Brenner H, Chang-Claude J, Hoffmeister M, Trautwein C, Luedde T. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019 Jul;25(7):1054-1056. doi: 10.1038/s41591-019-0462-y. Epub 2019 Jun 3.
Kaufmann J, Wentzensen N, Brinker TJ, Grabe N. Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. Oncotarget. 2019 Apr 2;10(26):2515-2529. doi: 10.18632/oncotarget.26808. eCollection 2019 Apr 2.
Kirchner M, Neumann O, Volckmar AL, Stögbauer F, Allgäuer M, Kazdal D, Budczies J, Rempel E, Brandt R, Talla SB, von Winterfeld M, Leichsenring J, Bochtler T, Krämer A, Springfeld C, Schirmacher P, Penzel R, Endris V, Stenzinger A. RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers (Basel). 2019 Sep 5;11(9). pii: E1309. doi: 10.3390/cancers11091309.
Klafke N, Mahler C, von Hagens C, Uhlmann L, Bentner M, Schneeweiss A, Mueller A, Szecsenyi J, Joos S. The effects of an integrated supportive care intervention on quality of life outcomes in outpatients with breast and gynecologic cancer undergoing chemotherapy: Results from a randomized controlled trial. Cancer Med. 2019 Jul;8(8):3666-3676. doi: 10.1002/cam4.2196. Epub 2019 May 21.
Kolberg HC, Schneeweiss A, Fehm TN, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux MP, Janni W, Hartkopf AD, Taran FA, Wallwiener M, Overkamp F, Tesch H, Ettl J, Lüftner D, Müller V, Schütz F, Fasching PA, Brucker SY. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd. 2019 May;79(5):470-482. doi: 10.1055/a-0887-0861. Epub 2019 May 21
Köppel M, Wiskemann J, Huber G, Eckert K. Körperliches Training vor Krebsoperationen am Gastrointestinaltrakt. link.springer.com/content/pdf/10.1007/s11377-019-0377-7
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. ⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.
Kriegsmann M, Roessler S, Kriegsmann K, Renner M, Longuespée R, Albrecht T, Loeffler M, Singer S, Mehrabi A, Vogel MN, Pathil A, Köhler B, Springfeld C, Rupp C, Weiss KH, Goeppert B. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. BMC Cancer. 2019 Jan 15;19(1):72. doi: 10.1186/s12885-018-5254-0.
Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer JU, Costa SD, Denkert C, Ditsch N, Gerber B, Hanusch C, Heil J, Hilfrich J, Huober JB, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Loibl S.
Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Adès L, Oelschlägel U, Platzbecker U. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2019 Dec 3. doi: 10.1038/s41375-019-0645-z. [Epub ahead of print]
Laakmann E, Witzel I, Fasching PA, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Zahm DM, Blohmer JU, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Loibl S. evelopment of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res. 2019 May 10;21(1):60. doi: 10.1186/s13058-019-1144-x.
Laban S, Gangkofner DS, Holzinger D, Schroeder L, Eichmüller SB, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende CC, Dyckhoff G, Boscolo-Rizzo P, Ezić J, Marienfeld R, Möller P, Kraus JM, Völkel G, Kestler HA, Brunner C, Schuler PJ, Wigand MC, Theodoraki MN, Doescher J, Hoffmann TK, Pawlita M, Waterboer T, Butt J. Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019 Dec 15;25(24):7405-7412. doi: 10.1158/1078-0432.CCR-19-1490. Epub 2019 Aug 23.
Liebers R, Jäger D. Surgical wound immunotherapy. Nat Nanotechnol. 2019 Jan;14(1):7-8. doi: 10.1038/s41565-018-0328-3.
Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12.
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158.
Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel). 2019 Oct;14(5):315-324. doi: 10.1159/000502603. Epub 2019 Sep 17.
Matthies LM, Taran FA, Keilmann L, Schneeweiss A, Simoes E, Hartkopf AD, Sokolov AN, Walter CB, Sickenberger N, Wallwiener S, Feisst M, Gass P, Lux MP, Schuetz F, Fasching PA, Sohn C, Brucker SY, Graf J, Wallwiener M. An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for easuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study. J Med Internet Res. 2019 Jan 22;21(1):e10004. doi: 10.2196/10004.
Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo WY, Loibl S, Long J, Lubiński J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkäs K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. Epub 2018 Dec 13.
Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke EM, Fasching P, Strumberg D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A, Marmé F. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. Breast. 2019 Jun;45:22-28. doi: 10.1016/j.breast.2019.02.002. Epub 2019 Feb 13.
Mavratzas A, Seitz J, Smetanay K, Schneeweiss A, Jäger D, Fremd C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol. 2020 Jan;16(3):4439-4453. doi: 10.2217/fon-2019-0468. Epub 2019 Dec 12.
Mehlis K, Woydack L, Winkler EC. [Ethical frameworks as a corrective in daily clinical practice? : Reflection on the significance of organizational ethics in tackling the challenges of economization in the medical system]. Med Klin Intensivmed Notfmed. 2019 May 10. doi: 10.1007/s00063-019-0587-2. [Epub ahead of print]
Michel LL, Sommer L, González Silos R, Lorenzo Bermejo J, von Au A, Seitz J, Hennigs A, Smetanay K, Golatta M, Heil J, Schütz F, Sohn C, Schneeweiss A, Marmé F. Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score. Breast Cancer Res Treat. 2019 Sep;177(2):437-446. doi: 10.1007/s10549-019-05314-9. Epub 2019 Jun 24.
Michel LL, Sommer L, González Silos R, Lorenzo Bermejo J, von Au A, Seitz J, Hennigs A, Smetanay K, Golatta M, Heil J, Schütz F, Sohn C, Schneeweiss A, Marmé F. Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index. PLoS One. 2019 Jan 31;14(1):e0211337. doi: 10.1371/journal.pone.0211337. eCollection 2019.
Mock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schröck E, Brors B, Stenzinger A, Jäger D, Schlenk R, Glimm H, Fröhling S, Horak P; DKTK MASTER Network. Community-driven development of a modified progression-free survival ratio for precision oncology. 2019 Nov 13;4(6):e000583. doi: 10.1136/esmoopen-2019-000583. eCollection 2019.
Mock A, Zschäbitz S, Kirsten R, Scheffler M, Wolf B, Herold-Mende C, Kramer R, Busch E, Jenzer M, Jäger D, Grüllich C. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. Cancer Immunol Immunother. 2019 Dec;68(12):2005-2014. doi: 10.1007/s00262-019-02428-3. Epub 2019 Nov 7.
Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019.
Oing C, Hentrich M, Lorch A, Gläser D, Rumpold H, Ochsenreither S, Richter S, Dieing A, Zschäbitz S, Pereira RR, Bokemeyer C, Seidel C. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. J Cancer Res Clin Oncol. 2020 Feb;146(2):449-455. doi: 10.1007/s00432-019-03071-2. Epub 2019 Dec 14.
Pal A, Zimmer P, Schmidt ME, Hummels M, Ulrich CM, Wiskemann J, Steindorf K. No Evidence for Effect of Exercise on Transcriptome of NK Cells in Breast Cancer Patients Undergoing Adjuvant Therapy: Results From a Pilot Study. Front Physiol. 2019 Jul 25;10:959. doi: 10.3389/fphys.2019.00959. eCollection 2019.
Pfuderer PL, Ballhausen A, Seidler F, Stark HJ, Grabe N, Frayling IM, Ager A, von Knebel Doeberitz M, Kloor M, Ahadova A. High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer. Br J Cancer. 2019 Aug;121(5):395-404. doi: 10.1038/s41416-019-0514-6. Epub 2019 Jul 30.
Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C, Roesch S, Mock A, Sahm F, Schmidt M, Jungwirth G, Zweckberger K, Lamszus K, Gousias K, Kessler AF, Grabe N, Loehr M, Ketter R, Urbschat S, Senft C, Westphal M, Abdollahi A, Debus J, von Deimling A, Unterberg A, Simon M, Herold-Mende CC. Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. Clin Cancer Res. 2019 Sep 1;25(17):5260-5270. doi: 10.1158/1078-0432.CCR-19-0389. Epub 2019 Jun 21.
Reul J, Frisch J, Engeland CE, Thalheimer FB, Hartmann J, Ungerechts G, Buchholz CJ. Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. Front Oncol. 2019 Feb 14;9:52. doi: 10.3389/fonc.2019.00052. eCollection 2019.
Roth S, Springfeld C, Diener MK, Tjaden C, Knebel P, Klaiber U, Michalski CW, Mieth M, Jäger D, Büchler MW, Hackert T. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. BMJ Open. 2019 Aug 20;9(8):e028696. doi: 10.1136/bmjopen-2018-028696. Erratum in: BMJ Open. 2019 Sep 19;9(9):e028696corr1.
Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.
Ruppert M, Korkmaz-Icöz S, Li S, Brlecic P, Németh BT, Oláh A, Horváth EM, Veres G, Pleger S, Grabe N, Merkely B, Karck M, Radovits T, Szabó G. Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy. Front Physiol. 2019 Jan 8;9:1869. doi: 10.3389/fphys.2018.01869. eCollection 2018.
Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, Deyle DR, Federspiel MJ, Fielding A, Galanis E, Lacy MQ, Leibovich BC, Liu MC, Muñoz-Alía M, Miest TC, Molina JR, Mueller S, Okuno SH, Packiriswamy N, Peikert T, Raffel C, Van Rhee F, Ungerechts G, Young PR, Zhou Y, Peng KW. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clin Proc. 2019 Sep;94(9):1834-1839. doi: 10.1016/j.mayocp.2019.05.006. Epub 2019 Jun 22. Review.
Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Duurland CL, van Unen V, Höllt T, van der Velden LA, van Egmond SL, Kortekaas KE, de Vos van Steenwijk PJ, van Poelgeest MIE, Welters MJP, van der Burg SH. The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival. Clin Cancer Res. 2019 Jan 1;25(1):240-252. doi: 10.1158/1078-0432.CCR-18-1749. Epub 2018 Sep 17.
Schlenk RF, Jaramillo S, Müller-Tidow C. What's new in consolidation therapy in AML? Semin Hematol. 2019 Apr;56(2):96-101. doi: 10.1053/j.seminhematol.2018.08.005. Epub 2018 Aug 29.
Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.
Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, Ringhoffer M, Hertenstein B, Martens UM, Grießhammer M, Bernhard H, Krauter J, Girschikofsky M, Wolf D, Lange E, Westermann J, Koller E, Kremers S, Wattad M, Heuser M, Thol F, Göhring G, Haase D, Teleanu V, Gaidzik V, Benner A, Döhner K, Ganser A, Paschka P, Döhner H. Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. Leukemia. 2019 Aug;33(8):1923-1933. doi: 10.1038/s41375-019-0395-y. Epub 2019 Feb 6.
Schlüter K, Schneider J, Sprave T, Wiskemann J, Rosenberger F. Feasibility of two high-intensity interval training protocols in cancer survivors. Med Sci Sports Exerc. 2019 Dec;51(12):2443-2450. doi: 10.1249/MSS.0000000000002081.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.
Schmidt M, Scherer S, Wiskemann J, Steindorf K. Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl). 2019 Jul;28(4):e13051. doi: 10.1111/ecc.13051. Epub 2019 Apr 29.
Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ. Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel). 2019 Dec 10;11(12). pii: E1987. doi: 10.3390/cancers11121987.
Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019 Jan;106:181-192. doi: 10.1016/j.ejca.2018.10.015. Epub 2018 Dec 5.
Schneider J*, Schlüter K*, Wiskemann J, Rosenberger F. Do we underestimate VO2max in cancer survivors? Findings from a supramaximal verification test. Appl Physiol Nutr Metab. 2019 Oct 11. doi: 10.1139/apnm-2019-0560. [Epub ahead of print]
Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V. Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.
Smetanay K, Junio P, Feißt M, Seitz J, Hassel JC, Mayer L, Matthies LM, Schumann A, Hennigs A, Heil J, Sohn C, Jaeger D, Schneeweiss A, Marmé F. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2019 Jan;173(1):135-143. doi: 10.1007/s10549-018-4983-8. Epub 2018 Sep 25.
Sprave T, Scharhag-Rosenberger F, Verma V, Förster R, Bruckner T, Schlampp I, Bostel T, Welzel T, Akbaba S, Rackwitz T, Nicolay NH, Grosu AL, Wiskemann J, Debus J, Rief H. Paravertebral Muscle Training in Patients with Unstable Spinal Metastases Receiving Palliative Radiotherapy: An Exploratory Randomized Feasibility Trial. Cancers (Basel). 2019 Nov 11;11(11). pii: E1771. doi: 10.3390/cancers11111771.
Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med. 2019 Mar;48(3 Pt 2):e159-e174. doi: 10.1016/j.lpm.2019.02.025. Epub 2019 Mar 15. Review.
Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Schuetz F, Sohn C, Bohlmann MK, Sütterlin M, Schneeweiss A, Wallwiener M. Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. Cancers (Basel). 2019 Mar 11;11(3). pii: E342. doi: 10.3390/cancers11030342.
Steindorf K, Clauss D, Tjaden C, Hackert T, Schneider L, Ulrich CM, Wiskemann J. Quality of Life, Fatigue, and Sleep Problems in Pancreatic Cancer Patients - A Randomized Trial on the Effects of Exercise. Dtsch Arztebl Int. 2019 Jul 8;116(27-28):471-478. doi: 10.3238/arztebl.2019.0471.
Steindorf K, Depenbusch J, Haussmann A, Tsiouris A, Schmidt L, Herrmann S, Sieverding M, Wiskemann J*, Ungar N*. Change patterns and determinants of physical activity differ between breast, prostate and colorectal cancer patients. Support Care Cancer. 2019 Nov 22. doi: 10.1007/s00520-019-05097-1. [Epub ahead of print]
Stock S, Übelhart R, Schubert ML, Fan F, He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, Hückelhoven-Krauss A, Gern U, Christ C, Hexel M, Schmitt A, Schmidt P, Krauss J, Jäger D, Müller-Tidow C, Dreger P, Schmitt M, Sellner L. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28.
Suarez-Carmona M, Chaorentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N. CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology. 2019 Jul 13;8(9):e1626193. doi: 10.1080/2162402X.2019.1626193. eCollection 2019.
Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2019 Aug 1;30(8):1404. doi: 10.1093/annonc/mdy538.
Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM. Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. Br J Sports Med. 2019 Jul;53(13):812. doi: 10.1136/bjsports-2018-099191. Epub 2018 Sep 4.
Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30.
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst. 2019 Apr 1;111(4):380-387. doi: 10.1093/jnci/djy152.
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, deGregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C. Response to Di Cosimo, Torri, and Porcu. J Natl Cancer Inst. 2019 Nov 1;111(11):1234-1235. doi: 10.1093/jnci/djz095. No abstract available.
Tsingos E, Höckendorf B, Sütterlin T, Kirchmaier S, Grabe N, Centanin L, Wittbrodt J. Retinal stem cells modulate proliferative parameters to coordinate post-embryonic morphogenesis in the eye of fish. Elife. 2019 Mar 26;8. pii: e42646. doi: 10.7554/eLife.42646.
Ungar N, Rupprecht FS, Steindorf K, Wiskemann J, Sieverding M. Worse or even better than expected? Outcome expectancies and behavioral experiences in the context of physical activity among cancer patients. J Health Psychol. 2019 Mar 11:1359105319832345. doi: 10.1177/1359105319832345. [Epub ahead of print]
Ungar N, Schmidt L, Gabrian M, Haussmann A, Tsiouris A, Sieverding M, Steindorf K*, Wiskemann J*. Which self-management strategies do health care professionals recommend to their cancer patients? An experimental investigation of patient age and treatment phas. J Behav Med. 2019 Apr;42(2):342-352. doi: 10.1007/s10865-018-9980-1. Epub 2018 Oct 23. *shared last authorship
Ungar N, Tsiouris A, Haussmann A, Herbolsheimer F, Steindorf K, Wiskemann J, Sieverding M. To rest or not to rest-Health care professionals' attitude toward recommending physical activity to their cancer patients. Psychooncology. 2019 Apr;28(4):784-791. doi: 10.1002/pon.5020. Epub 2019 Feb 20.
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol. 2019 Sep 1;37(25):2226-2234. doi: 10.1200/JCO.18.01842. Epub 2019 May 13.
Untch M, Schneeweiss A, Krug D, Kühn T, Loibl S. Post-Neoadjuvant Therapy. Breast Care (Basel). 2019 Dec;14(6):409-413. doi: 10.1159/000504661. Epub 2019 Nov 27.
Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching PA, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604. doi: 10.1055/a-0897-6457. Epub 2019 Jun 14.
Vallet S, Fan F, Malvestiti S, Pecherstorfer M, Sattler M, Schneeweiss A, Schulze-Bergkamen H, Opferman JT, Cardone MH, Jäger D, Podar K. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast Cancer Res Treat. 2019 Feb;173(3):585-596. doi: 10.1007/s10549-018-5022-5. Epub 2018 Oct 29.
van Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, May AM, Buffart LM. Moderators of effects of exercise on cancer-related fatigue: meta-analysis of individual patient data.
von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Munzinger J, Edler L, Efferth T, Schneeweiss A, Strowitzki T. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2). Phytomedicine. 2019 Feb 15;54:140-148. doi: 10.1016/j.phymed.2018.09.178. Epub 2018 Sep 17.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
Welslau M, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Kolberg HC, Nabieva N, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Schneeweiss A, Fehm TN. Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099. doi: 10.1055/a-1001-9952. Epub 2019 Oct 22.
Wiskemann J*, Clauss D*, Tjaden C, Hackert T, Schneider L, Ulrich CM, Steindorf K. Progressive Resistance Training to Impact Physical Fitness and Body Weight in Pancreatic Cancer Patients. Pancreas. 2019 Feb;48(2):257-266. doi: 10.1097/MPA.0000000000001221. *shared first authorship.
Wiskemann J, Köppel M, Biazeck B. Sport und Bewegung nach Krebstherapie – OnkoAktiv als ein Beispiel. https://link.springer.com/article/10.1007/s11377-019-0376-8
Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, Winkler EC. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications
Yuan B, Schafferer S, Tang Q, Scheffler M, Nees J, Heil J, Schott S, Golatta M, Wallwiener M, Sohn C, Koal T, Wolf B, Schneeweiss A, Burwinkel B. A plasma metabolite panel as biomarkers for early primary breast cancer detection. Int J Cancer. 2019 Jun 1;144(11):2833-2842. doi: 10.1002/ijc.31996. Epub 2019 Jan 4.
Zimmer P, Schmidt M, Berdel B, Wiskemann J, Kellner KH, Debus J, Ulrich CM, Opitz A, Steindorf K. Resistance Exercise Reduces Kynurenine Pathway Metabolites in Breast Cancer Patients Undergoing Radiotherapy. Front Oncol. 2019 Sep 25;9:962. doi: 10.3389/fonc.2019.00962. eCollection 2019.

Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Fröhling S, Penzel R, Thomas M, Schirmacher P, Stenzinger A. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Transl Lung Cancer Res. 2018 Dec;7(6):703-715. doi: 10.21037/tlcr.2018.08.14. Review. PubMed PMID: 30505715; PubMed Central PMCID: PMC6249620.
Leichsenring J, Stögbauer F, Volckmar AL, Buchhalter I, Oliveira C, Kirchner M, Fröhling S, Hassel J, Enk A, Schirmacher P, Endris V, Penzel R, Stenzinger A. Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology. 2018 Dec;50(7):703-710. doi: 10.1016/j.pathol.2018.08.004. Epub 2018 Oct 20. PubMed PMID: 30348504.
Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018 Nov 15;7. doi: 10.7554/eLife.41305. PubMed PMID: 30431433; PubMed Central PMCID: PMC6277197.
Lier A, Penzel R, Heining C, Horak P, Fröhlich M, Uhrig S, Budczies J, Kirchner M, Volckmar AL, Hutter B, Kreutzfeldt S, Endris V, Richter D, Wolf S, Pfütze K, Neumann O, Buchhalter I, Morais de Oliveira CM, Singer S, Leichsenring J, Herpel E, Klauschen F, Jost PJ, Metzeler KH, Schulze-Osthoff K, Kopp HG, Kindler T, Rieke DT, Lamping M, Brandts C, Falkenhorst J, Bauer S, Schröck E, Folprecht G, Boerries M, von Bubnoff N, Weichert W, Brors B, Lichter P, von Kalle C, Schirmacher P, Glimm H, Fröhling S, Stenzinger A. Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precis Oncol. 2018 Nov;2:1-13. doi: 10.1200/PO.18.00171. PubMed PMID: 35135162.
Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26. PubMed PMID: 30049810; PubMed Central PMCID: PMC6172562.
Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22. PubMed PMID: 29654265.
Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub 2018 May 25. PubMed PMID: 29802158.
Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A. Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDH^mut-like DNA hypermethylation. Nature. 2018 Aug;560(7718):E28. doi: 10.1038/s41586-018-0403-9. PubMed PMID: 30069041.
Koelsche C, Hartmann W, Schrimpf D, Stichel D, Jabar S, Ranft A, Reuss DE, Sahm F, Jones DTW, Bewerunge-Hudler M, Trautmann M, Klingebiel T, Vokuhl C, Gessler M, Wardelmann E, Petersen I, Baumhoer D, Flucke U, Antonescu C, Esteller M, Fröhling S, Kool M, Pfister SM, Mechtersheimer G, Dirksen U, von Deimling A. Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. Mod Pathol. 2018 Aug;31(8):1246-1256. doi: 10.1038/s41379-018-0045-3. Epub 2018 Mar 23. PubMed PMID: 29572501; PubMed Central PMCID: PMC7484949.
Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. Eur J Haematol. 2018 Jul;101(1):115-118. doi: 10.1111/ejh.13072. Epub 2018 May 11. PubMed PMID: 29624748.
Vogl T, Stratis A, Wixler V, Völler T, Thurainayagam S, Jorch SK, Zenker S, Dreiling A, Chakraborty D, Fröhling M, Paruzel P, Wehmeyer C, Hermann S, Papantonopoulou O, Geyer C, Loser K, Schäfers M, Ludwig S, Stoll M, Leanderson T, Schultze JL, König S, Pap T, Roth J. Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation. J Clin Invest. 2018 May 1;128(5):1852-1866. doi: 10.1172/JCI89867. Epub 2018 Apr 3. PubMed PMID: 29611822; PubMed Central PMCID: PMC5919817.
Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, Glimm H, Brors B, Beißbarth T. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. Genome Med. 2018 Mar 15;10(1):18. doi: 10.1186/s13073-018-0529-2. PubMed PMID: 29544535; PubMed Central PMCID: PMC5856211.
Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res. 2018 Feb 1;24(3):608-618. doi: 10.1158/1078-0432.CCR-17-2684. Epub 2017 Nov 10. PubMed PMID: 29127121; PubMed Central PMCID: PMC5796864.
Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0. PubMed PMID: 29321523; PubMed Central PMCID: PMC5762758.
Martins LR, Bung RK, Koch S, Richter K, Schwarzmüller L, Terhardt D, Kurtulmus B, Niehrs C, Rouhi A, Lohmann I, Pereira G, Fröhling S, Glimm H, Scholl C. Stk33 is required for spermatid differentiation and male fertility in mice. Dev Biol. 2018 Jan 1;433(1):84-93. doi: 10.1016/j.ydbio.2017.11.007. Epub 2017 Nov 16. PubMed PMID: 29155043.

Fröhling S. Many Roads Lead to snoRNAs: The Ever-Expanding Universe of Non-Coding RNAs in Acute Myeloid Leukemia. Hemasphere. 2017 Dec;1(1):e14. doi: 10.1097/HS9.0000000000000014. eCollection 2017 Dec. PubMed PMID: 31723743; PubMed Central PMCID: PMC6745981.
Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8. PubMed PMID: 29144447.
Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T. Genomics of Immunotherapy-Associated Hyperprogressors-Letter. Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. PubMed PMID: 29030332.
Trautmann M, Menzel J, Bertling C, Cyra M, Isfort I, Steinestel K, Elges S, Grünewald I, Altvater B, Rossig C, Fröhling S, Hafner S, Simmet T, Åman P, Wardelmann E, Huss S, Hartmann W. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. Clin Cancer Res. 2017 Oct 15;23(20):6227-6238. doi: 10.1158/1078-0432.CCR-17-0130. Epub 2017 Jun 21. PubMed PMID: 28637688.
Heining C, Horak P, Gröschel S, Glimm H, Fröhling S. [Personalized oncology]. Radiologe. 2017 Oct;57(10):804-811. doi: 10.1007/s00117-017-0297-9. Review. PubMed PMID: 28875369.
Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20. PubMed PMID: 28735071.
Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Cold Spring Harb Mol Case Stud. 2017 Sep;3(5). doi: 10.1101/mcs.a001974. Print 2017 Sep. PubMed PMID: 28619747; PubMed Central PMCID: PMC5593153.
Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S. Precision oncology based on omics data: The NCT Heidelberg experience. Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21. PubMed PMID: 28597939.
Budczies J, Bockmayr M, Klauschen F, Endris V, Fröhling S, Schirmacher P, Denkert C, Stenzinger A. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes Cancer. 2017 Aug;56(8):651-659. doi: 10.1002/gcc.22468. Epub 2017 May 31. PubMed PMID: 28466543.
Giessler KM, Kleinheinz K, Huebschmann D, Balasubramanian GP, Dubash TD, Dieter SM, Siegl C, Herbst F, Weber S, Hoffmann CM, Fronza R, Buchhalter I, Paramasivam N, Eils R, Schmidt M, von Kalle C, Schneider M, Ulrich A, Scholl C, Fröhling S, Weichert W, Brors B, Schlesner M, Ball CR, Glimm H. Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J Exp Med. 2017 Jul 3;214(7):2073-2088. doi: 10.1084/jem.20162017. Epub 2017 Jun 1. PubMed PMID: 28572216; PubMed Central PMCID: PMC5502434.
Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J, Glimm H. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. EMBO Mol Med. 2017 Jul;9(7):918-932. doi: 10.15252/emmm.201607354. PubMed PMID: 28526679; PubMed Central PMCID: PMC5494525.
Zhou C, Martinez E, Di Marcantonio D, Solanki-Patel N, Aghayev T, Peri S, Ferraro F, Skorski T, Scholl C, Fröhling S, Balachandran S, Wiest DL, Sykes SM. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. 2017 May;31(5):1196-1205. doi: 10.1038/leu.2016.329. Epub 2016 Nov 14. PubMed PMID: 27840425; PubMed Central PMCID: PMC5473421.
Hernandez Maganhi S, Jensen P, Caracelli I, Zukerman Schpector J, Fröhling S, Friedman R. Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein. Protein Sci. 2017 Apr;26(4):870-879. doi: 10.1002/pro.3135. Epub 2017 Mar 6. PubMed PMID: 28168755; PubMed Central PMCID: PMC5368058.
Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. Clin Cancer Res. 2017 Feb 15;23(4):962-973. doi: 10.1158/1078-0432.CCR-16-0860. Epub 2016 Aug 17. PubMed PMID: 27535980.
Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, Enk A, Hassel JC. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17. PubMed PMID: 27061826.
Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Oncotarget. 2017 Jan 31;8(5):7678-7690. doi: 10.18632/oncotarget.13841. PubMed PMID: 28032595; PubMed Central PMCID: PMC5352352.
Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology. 2017;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017. PubMed PMID: 28405504; PubMed Central PMCID: PMC5384369.
Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446. PubMed PMID: 27687311.

Słabicki M, Lee KS, Jethwa A, Sellner L, Sacco F, Walther T, Hüllein J, Dietrich S, Wu B, Lipka DB, Oakes CC, Mamidi S, Pyrzyńska B, Winiarska M, Oleś M, Seifert M, Plass C, Kirschfink M, Boettcher M, Gołąb J, Huber W, Fröhling S, Zenz T. Dissection of CD20 regulation in lymphoma using RNAi. Leukemia. 2016 Dec;30(12):2409-2412. doi: 10.1038/leu.2016.230. Epub 2016 Aug 18. PubMed PMID: 27560109.
Horak P, Fröhling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016;1(5):e000094. doi: 10.1136/esmoopen-2016-000094. eCollection 2016. Review. PubMed PMID: 27933214; PubMed Central PMCID: PMC5133384.
Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180. doi: 10.1101/mcs.a001180. PubMed PMID: 27900363; PubMed Central PMCID: PMC5111004.
Bochtler T, Fröhling S, Weichert W, Endris V, Thiede C, Hutter B, Hundemer M, Ho AD, Krämer A. Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001123. doi: 10.1101/mcs.a001123. PubMed PMID: 27626069; PubMed Central PMCID: PMC5002926.
Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer. 2016 Aug;55(8):626-39. doi: 10.1002/gcc.22365. Epub 2016 May 30. PubMed PMID: 27106868.
Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20. PubMed PMID: 27099147; PubMed Central PMCID: PMC4920675.
Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jäger D, Fröhling S, Springfeld C. [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. Z Gastroenterol. 2016 May;54(5):426-30. doi: 10.1055/s-0042-103498. Epub 2016 May 12. PubMed PMID: 27171333.
Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia. 2016 Apr;30(4):937-46. doi: 10.1038/leu.2015.319. Epub 2015 Nov 19. PubMed PMID: 26582644.
Ronellenfitsch U, Dimitrakopoulou-Strauss A, Jakob J, Kasper B, Nowak K, Pilz LR, Attenberger U, Gaiser T, Egerer G, Fröhling S, Derigs HG, Schwarzbach M, Hohenberger P. Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open. 2016 Jan 6;6(1):e009558. doi: 10.1136/bmjopen-2015-009558. PubMed PMID: 26739732; PubMed Central PMCID: PMC4716254.

Husedzinovic A, Ose D, Schickhardt C, Fröhling S, Winkler EC. Stakeholders' perspectives on biobank-based genomic research: systematic review of the literature. Eur J Hum Genet. 2015 Dec;23(12):1607-14. doi: 10.1038/ejhg.2015.27. Epub 2015 Mar 4. Review. PubMed PMID: 25735479; PubMed Central PMCID: PMC4795193.
Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11. PubMed PMID: 26065650.
Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, Jin L, Seo JH, Shan C, Arbiser JL, Cohen C, Brat D, Miziorko HM, Kim E, Abdel-Wahab O, Merghoub T, Fröhling S, Scholl C, Tamayo P, Barbie DA, Zhou L, Pollack BP, Fisher K, Kudchadkar RR, Lawson DH, Sica G, Rossi M, Lonial S, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, He C, Kang S, Chen J. Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell. 2015 Aug 6;59(3):345-358. doi: 10.1016/j.molcel.2015.05.037. Epub 2015 Jul 2. PubMed PMID: 26145173; PubMed Central PMCID: PMC4530073.
Bochtler T, Fröhling S, Krämer A. Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. Leukemia. 2015 Jun;29(6):1243-52. doi: 10.1038/leu.2015.32. Epub 2015 Feb 12. Review. PubMed PMID: 25673237.
Azoitei N, Fröhling S, Scholl C, Seufferlein T. PRKD2: A two-pronged kinase crucial for the tumor-supporting activity of HSP90. Mol Cell Oncol. 2015 Apr-Jun;2(2):e981444. doi: 10.4161/23723556.2014.981444. eCollection 2015 Apr-Jun. PubMed PMID: 27308444; PubMed Central PMCID: PMC4904966.
Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. Epub 2014 Oct 17. PubMed PMID: 25322685.
Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015 Feb 23;5:8535. doi: 10.1038/srep08535. PubMed PMID: 25705018; PubMed Central PMCID: PMC4336936.

Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Fröhling S, Scholl C, Seufferlein T. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Res. 2014 Dec 1;74(23):7125-36. doi: 10.1158/0008-5472.CAN-14-1017. Epub 2014 Oct 8. PubMed PMID: 25297628; PubMed Central PMCID: PMC4315623.
Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014 Nov;124(11):5074-84. doi: 10.1172/JCI76539. Epub 2014 Oct 20. PubMed PMID: 25329694; PubMed Central PMCID: PMC4347247.
Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24. PubMed PMID: 24764564; PubMed Central PMCID: PMC4190617.

Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20. PubMed PMID: 23690412.
Rouhi A, Fröhling S. Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer. Oncotarget. 2013 Feb;4(2):174-5. doi: 10.18632/oncotarget.896. PubMed PMID: 23563447; PubMed Central PMCID: PMC3712560.
Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia. 2013 Feb;27(2):353-61. doi: 10.1038/leu.2012.208. Epub 2012 Jul 19. PubMed PMID: 22810507.
Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest. 2013 Jan;123(1):299-314. doi: 10.1172/JCI64745. Epub 2012 Dec 3. PubMed PMID: 23202735; PubMed Central PMCID: PMC3533294.

Fröhling S. Widespread over-expression of the non-clustered homeobox gene HLX in acute myeloid leukemia. Haematologica. 2012 Oct;97(10):1453. doi: 10.3324/haematol.2012.076612. PubMed PMID: 23053668; PubMed Central PMCID: PMC3487543.
Fröhling S. Ligand-induced MET signaling as targetable codependence in acute myeloid leukemia. Haematologica. 2012 Aug;97(8):1118. doi: 10.3324/haematol.2012.073635. PubMed PMID: 22855844; PubMed Central PMCID: PMC3409806.
Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26. PubMed PMID: 22451720; PubMed Central PMCID: PMC3328372.
Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012 Mar 1;119(9):2114-21. doi: 10.1182/blood-2011-08-375758. Epub 2011 Dec 20. PubMed PMID: 22186996.
Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, Scholl C, Fröhling S, Carr SA, Stern AM, Schreiber SL, Golub TR. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2860-5. doi: 10.1073/pnas.1120589109. Epub 2012 Feb 9. PubMed PMID: 22323609; PubMed Central PMCID: PMC3286931.
Bullinger L, Fröhling S. Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights. Semin Oncol. 2012 Feb;39(1):37-46. doi: 10.1053/j.seminoncol.2011.11.005. Review. PubMed PMID: 22289490.
Fröhling S, Scholl C. STK33 kinase is not essential in KRAS-dependent cells--letter. Cancer Res. 2011 Dec 15;71(24):7716; author reply 7717. doi: 10.1158/0008-5472.CAN-11-2495. Epub 2011 Nov 29. PubMed PMID: 22127923.
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011 Sep 2;146(5):697-708. doi: 10.1016/j.cell.2011.07.032. PubMed PMID: 21884932; PubMed Central PMCID: PMC3826540.
Koo S, Huntly BJ, Wang Y, Chen J, Brumme K, Ball B, McKinney-Freeman SL, Yabuuchi A, Scholl C, Bansal D, Zon LI, Fröhling S, Daley GQ, Gilliland DG, Mercher T. Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica. 2010 Oct;95(10):1642-50. doi: 10.3324/haematol.2010.023168. Epub 2010 May 21. PubMed PMID: 20494928; PubMed Central PMCID: PMC2948088.
Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010 Aug 10;28(23):3724-9. doi: 10.1200/JCO.2010.28.6468. Epub 2010 Jul 12. PubMed PMID: 20625124.
Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Fröhling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010 Aug;16(8):903-8. doi: 10.1038/nm.2187. Epub 2010 Jul 8. PubMed PMID: 20616797; PubMed Central PMCID: PMC3090658.
Zenz T, Fröhling S, Mertens D, Döhner H, Stilgenbauer S. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010 Mar;23(1):71-84. doi: 10.1016/j.beha.2009.12.003. Review. PubMed PMID: 20620972.
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21. PubMed PMID: 19847166; PubMed Central PMCID: PMC2783335.
Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017. PubMed PMID: 19490892; NIHMSID:NIHMS121220.
Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2009 Jan;94(1):54-60. doi: 10.3324/haematol.13378. Epub 2008 Dec 4. PubMed PMID: 19059939; PubMed Central PMCID: PMC2625424.
George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397. PubMed PMID: 18923525; PubMed Central PMCID: PMC2587486.

Alle Publikationen

Weiter zu PubMed

Ausgewählte Publikationen

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012-1996

Alle Publikationen